Executive summary
Inspired by unprecedented improvements in human health and development in recent decades,
our world has embarked on a quest that only a generation ago would have been considered
unreachable—achieving sustainable health and development for all. Improving the health
and wellbeing of the world's people is at the core of the Sustainable Development
Goals (SDGs), reflected in targets that call for ending the epidemics of AIDS, tuberculosis,
and malaria; achieving enormous improvements in maternal and child health; and tackling
the growing burden of non-communicable diseases (NCDs). Attaining universal health
coverage is the means by which these ambitious health targets are to be achieved.
Although on their face, the SDGs reflect an unprecedented level of global solidarity
and resolve, the trends that increasingly define our world in 2018 are inconsistent
with both the sentiments that underlie the SDGs and the ethos that generated such
striking health and development gains in recent years. Democracy is in retreat, and
in many countries the space for civil society is declining and the human rights environment
deteriorating. Official development assistance for health has stalled, as an inward-looking
nationalism has in many places supplanted recognition of the need for global collaboration
to address shared challenges. The loss of momentum on global health ignores the urgent
need to strengthen health systems to address the steady growth of NCDs, which now
account for seven of ten deaths worldwide.
Recent trends in the HIV response are especially concerning. Although the number of
new HIV infections and AIDS-related deaths have markedly decreased since the epidemic
peaked, little progress has been made in reducing new infections in the past decade.
Without further reductions in HIV incidence, a resurgence of the epidemic is inevitable,
as the largest ever generation of young people age into adolescence and adulthood.
Yet where vigilance and renewed efforts are needed, there are disturbing indications
that the world's commitment is waning. Allowing the HIV epidemic to rebound would
be catastrophic for the communities most affected by HIV and for the broader field
of global health. If the world cannot follow through on HIV, which prompted such an
extraordinary global mobilisation, hopes for achieving the ambitious health aims outlined
in the SDGs will inevitably dim.
At this moment of uncertainty for the future of the HIV response and for global health
generally, the International AIDS Society and The Lancet convened an international
Commission of global experts and stakeholders to assess the future of the HIV response
in the context of a more integrated approach to health. A central finding of the Commission
is that the HIV epidemic is not on track to end and that existing tools are insufficient.
Although antiretroviral therapy (ART) has transformed the HIV response by averting
deaths, improving quality of life, and preventing new HIV infections, HIV treatment
alone will not end the epidemic. The UNAIDS 90-90-90 approach must be accompanied
by a similarly robust commitment to scaled-up primary HIV prevention and to the development
of a preventive vaccine and a functional cure for HIV. Ironically, the diminishing
energy on HIV is occurring at the moment when lessons learned during the HIV response
could serve as pathfinders in the quest for sustainable health for all.
Key messages
•
The HIV pandemic is not on track to end, and the prevailing discourse on ending AIDS
has bred a dangerous complacency and may have hastened the weakening of global resolve
to combat HIV
•
Existing HIV tools and strategies are insufficient, and although dramatic gains can
be made through maximizing existing prevention and treatment strategies, the HIV pandemic
is likely to remain a major global challenge for the foreseeable future
•
Tens of millions of people will require sustained access to antiretroviral therapy
for decades to come, vigilance will be needed to prevent a resurgence of the epidemic
as the largest-ever generation of young people age into adolescence and young adulthood,
and intensified efforts are required to address HIV among populations and settings
that are being left behind
•
Allowing the pandemic to rebound after achieving such remarkable progress would not
only increase the human and financial costs of HIV, but it would potentially demoralise
the global health field and diminish support for similarly ambitious global health
undertakings
•
A rejuvenated global effort on HIV is essential; to renew and strengthen the global
HIV response, the world's impressive commitment to the scaling up of HIV treatment
services must be matched by a similarly robust commitment to expanded access to HIV
prevention
•
The HIV response must make common cause with the broader global health field to herald
a new era of global solidarity for health, and specific action is urgently needed
to respond to the rapidly rising health toll associated with non-communicable diseases,
including taking health into account in the development of public policies of all
kinds. HIV services should, where feasible, be integrated with broader health services,
in co-located sites where possible, with the aim of improving both HIV-related and
non-HIV-specific health outcomes; greater integration of HIV and global health must
preserve and build on key attributes of the HIV response, including participatory
community and civil society engagement and an ironclad commitment to human rights,
gender equality, and equitable access to health and social justice
•
The new era of global health solidarity should focus on the development of robust,
flexible, people-centred health systems to end communicable diseases, develop effective
measures to address the steady rise of non-communicable diseases, achieve universal
health coverage, provide coordinated services tailored to the needs of health service
users, and effectively address the social and structural determinants of health
From its inception, the HIV response was a unique undertaking, apart from the broader
health system. Although elements of a disease-specific approach will and should be
retained, the future of the HIV response will also depend on finding opportunities
for integrating HIV services more closely within health systems. Wholesale abandonment
of vertical HIV funding would involve considerable risks, as the laser-like focus
on a single disease accounts in large measure for the HIV response's successes. Unique
attributes that have defined the HIV response (including its multisectoral and inclusive
approach, engagement of civil society, emphasis on equity and human rights, galvanisation
of scientific innovation, and foundation of global collaboration and problem solving)
must be preserved and mainstreamed across global health practice.
Whether to integrate HIV within broader health systems is not an either–or choice,
and optimal paths will differ between settings, populations, and services. To be effective,
more integrated approaches must yield improvements both to HIV-related and non-HIV-related
health outcomes. In most cases, approaches to integration will and should be incremental,
allowing learning by doing. To assess the health and financial benefits of such win-win
scenarios, the Commission engaged modellers to examine different scenarios for incremental
integration of HIV-related and non-HIV-related services. These include: models in
South Africa and Kenya for screening of HIV alongside screening for diabetes, hypertension,
and other NCDs; integration of HIV in reproductive health services in Nigeria; integrated
management of HIV and sexually transmitted infections in India; and integration of
harm reduction and overdose services and ART for people who use drugs in Russia. In
each of these scenarios, integrated approaches generated concrete improvements in
HIV and broader health outcomes. With one exception (antiretroviral pre-exposure prophylaxis
[PrEP] in India), integrated models were consistently found to be cost-effective.
The HIV community must make common cause with the global health field— to make universal
health coverage a reality, to substantially increase the share of resources devoted
to health, and to build worldwide recognition of health as key to progress across
the breadth of the SDGs. The global health field must take a leading role in resisting
the turn towards authoritarianism, xenophobia, and austerity with respect to essential
public health investments. In a time of fragmentation and uncertainty, the global
health field can aid in reminding all of us of our common humanity. Health systems
must be designed to meet the needs of the people they serve, including having the
capacity to address multiple health problems simultaneously. No one can be left behind
in our efforts to achieve sustainable health. Recognising health as an investment,
major new resources (from national governments, the international community, and the
private sector, involving innovative financing mechanisms) must be mobilised to support
stronger, sustainable, and people-centred health systems.
Global health and HIV
The SDGs sharply elevate global health and development aspirations, contemplating
a world that is far more prosperous, secure, healthy, and equitable, where human rights
and dignity are universally respected, and where human development unfolds in a manner
that preserves the natural environment. Yet, the 3 years that have passed since the
SDGs were agreed have dimmed prospects for achieving many of these visionary aims.
By contrast with the international solidarity, shared commitment, and increased investments
that characterised the era of the Millennium Development Goals (MDGs), much of the
world has, since 2015, turned inward and toward authoritarianism, repression, a diminished
role for civil society, a policy of austerity for public investments, and suspicion
of international cooperation. As a result of civil conflicts that have yet to elicit
an appropriate international response, more people than ever have been forced from
their homes and countries. At a time when the fruits of scientific advances are so
evident, denial in many quarters of the role of humankind in the degradation of our
environment threatens the very health and wellbeing of our planet and our civilisations.
Among the reasons why the world opted for such an ambitious agenda for the SDGs was
the success of the HIV response. As a result of a worldwide mobilisation, the incidence
of HIV infections peaked and began to decrease in all parts of the world, and AIDS-related
mortality decreased from 1·9 million in 2005 to 1·0 million in 2016.
1
The HIV response has not been an unalloyed story of achievement, as the world's capacity
to respond effectively to the epidemic has been undermined by 15 years of relative
inaction in the epidemic's early stages, an approach to epidemic management that has
undervalued primary prevention, and the enduring stigma associated with HIV.
The broader global health community, facing both historic opportunities and profound
challenges, could potentially benefit from lessons learned from the successes and
failures of the global HIV response. With its multisectoral and inclusive approach,
mobilisation of political commitment, engagement of civil society at every level,
emphasis on equity and human rights, galvanisation of scientific innovation, and foundation
of global collaboration and problem solving, the HIV response has properly been cited
as a model for the future of global health.
2
The global health challenge remains immense, with millions of people in low-income
and middle-income countries (LMICs) dying each year from causes that have either been
largely eradicated or are decreasing in prevalence in high-income countries (figure
1
).
3
Whether the world is prepared to meet these challenges is unclear. Although the incidence
of communicable, maternal, neonatal, and nutritional diseases have decreased worldwide
since 1980,
3
the most recent projections indicate that financial resources available for health
programmes in LMICs are likely to fall far short of amounts needed to reach the health
targets set forth in the SDGs.
4
Persistent weaknesses of health systems undermine prospects for progress in addressing
the full panoply of health challenges.
Figure 1
Ten leading causes of death in 2015
(A) Low-income economies. (B) Low-middle-income economies. (C) Upper-middle-income
economies. (D) High-income economies. Source: WHO.
At the very moment when HIV could serve as a pathfinder for global health, there are
signs that global commitment to build on the gains achieved against HIV thus far is
waning. From 2013 to 2016, international HIV assistance was reduced by roughly 20%,
from almost US$10 billion to US$8·1 billion.
5
Relinquishing the fight against HIV before it is over would have disastrous consequences,
both for people affected by HIV and for the broader global health community. Unless
further investments are made to accelerate expansion of HIV prevention and treatment
programmes, the HIV epidemic is likely to rebound and grow far more serious in the
coming years, especially as the world's largest-ever cohort of young people age into
adolescence and young adulthood.
6
Notwithstanding the enormous progress that has been made in the HIV response, HIV
remains “the epidemic of our time”.
7
In 2015–16, an estimated 36·7–38·8 million people were living with HIV worldwide,
including 1·9–2·5 million newly infected in 2015.1, 8 More than 35 million people
have died of AIDS-related causes; 1·0 million of these deaths were in 2016.
9
A refusal to follow through to achieve long-term control of the epidemic would merely
repeat a longstanding pattern in global health, when failure to sustain a surge in
global interest in combating particular health threats allows these epidemics to return
in force. The history of malaria elimination efforts is a case in point, as the failure
to sustain malaria-related control programmes, funding, and research investments led
to an abandonment of the global malaria elimination campaign in 1969 and subsequent
increases in the global malaria burden.
10
At a moment when the means to improve human health are greater than ever, allowing
a resurgence of HIV through neglect and apathy could deal a blow from which the broader
cause of global health could need decades to recover.
The relationship between the HIV response and the broader global health field is multilayered
and bidirectional. Even as the HIV response offers important lessons from which global
health can learn, it is also clear that controlling the HIV epidemic will depend in
large measure on the broader global health and development fields. However, the exceptionalist
approach to the HIV epidemic, in which the HIV response has often unfolded as a vertical
undertaking, distinct from other health programmes, has achieved historic results
and should not be jettisoned lightly.
Both the HIV response and the broader global health field share a commitment to the
development of health systems that are capable of addressing several health challenges
at the same time. In many settings, robust, if still flawed, service systems have
been developed for certain populations (eg, pregnant women, children) or for priority
health conditions (eg, maternal and child health, HIV, and other communicable diseases).
However, health systems as a whole are largely unprepared for providing care that
is holistic, universal, and well coordinated. In the still-early years of the SDG
era, the gap between reality and the vision of sustainable health remains gaping.
In the midst of uncertainty about the long-term feasibility of an exceptionalist HIV
approach and the prospects for achieving the lofty health targets in the SDGs, the
International AIDS Society (IAS)-Lancet Commission on the Future of Global Health
and the HIV Response was established in 2016 to critically examine future prospects
for global health and the HIV response. The Commission was tasked with assessing the
future of the HIV response in a more integrated global health and development agenda,
with the aim of advising how best to achieve global control of the HIV pandemic in
an era in which health and development priorities are proliferating. The Commission
studied the history of the HIV response to discern how experience in responding to
HIV might inform and strengthen global health more broadly. Modelling exercises were
undertaken to assess the effect of various approaches to improve integration of HIV
and non-HIV-related services. The most salient threats to global health and to the
goal of universal health coverage were identified.
With this report, we summarise the findings of the Commission, and we seek to articulate
a vision for the future of the HIV response and global health that builds common cause
across health and development movements and sectors. Rather than despair over the
trends and patterns of the past several years, we must instead look to the extraordinary
achievements of the past two decades to embolden us and reinforce our resolve to rejuvenate
the HIV response and strengthen the broader cause of global health. By taking on board
the lessons of the HIV response, the global health field can be made fit for the purpose
of realising the vision of sustainable health for all. Global health can serve as
a driving force to repudiate and discredit the continuing retreat from international
solidarity, human rights, reason, scientific evidence, and open societies. Global
health can serve as a pioneer in a re-engineering of the development project, from
one based on charity from the high-income countries to one that tackles the central
determinants of global health inequities. Just as the HIV response has demonstrated
that global problems demand global solutions, the future health and wellbeing of our
planet relies on us to recognise, celebrate, and build on our common humanity.
With respect to the flagging response to HIV, the Commission hopes that this report
serves as a wake-up call. Without a thorough rejuvenation of the HIV response and
a change of course, we are likely to see a resurgence of the epidemic. After such
history-making successes from unprecedented global solidarity and collaboration, the
world can and must do better.
To realise the vision of sustainable health for all, we must ensure that health systems
are equipped to bring communicable diseases under control and to respond effectively
to the growing burden of NCDs. A focused response and categorical HIV funding will
remain crucial to avoid a resurgence of HIV and to bring the global pandemic under
control. However, immediate and incremental steps are needed to strategically integrate
HIV services into co-located primary care platforms and toward the longer-term goal
of creating fully integrated, co-located, and patient-centred health-service systems.
Global Health in 2018: new ambitions and growing threats
The Agenda for Sustainable Development envisages “a world free from poverty, hunger,
disease and want, where all life can thrive.”
11
SDG 3 calls for concerted action to ensure healthy lives and promote wellbeing for
all at all ages.
11
SDG 3 also calls for ending the epidemics of AIDS, tuberculosis, malaria, and neglected
tropical diseases; eliminating preventable deaths in children younger than 5 years;
and reducing by a third the number of deaths from NCDs.
11
Under the Agenda for Sustainable Development, universal health coverage serves as
the primary vehicle for continuing and fully leveraging the momentum on health.
11
The health targets of SDG 3 build on historic gains made under the MDGs (panel 1
).
12
The health gains during the MDG era coincided with, and were enabled by, advances
across the broader development agenda. Whereas nearly half of the population in LMICs
lived on less than $1·25 per day in 1990, this proportion had fallen to 14% by 2015.
12
Primary school attendance worldwide increased between 2000 and 2015, and differences
in secondary school attendance between boys and girls diminished or disappeared altogether
in some regions.
12
Panel 1
Health targets for Sustainable Development Goal 3
•
By 2030, reduce the global maternal mortality ratio to less than 70 deaths per 100 000
livebirths
•
By 2030, end preventable deaths of newborn babies and children younger than 5 years,
with all countries aiming to reduce neonatal mortality to at least as low as 12 deaths
per 1000 livebirths and under-5 mortality to at least as low as 25 deaths per 1000
livebirths
•
By 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical
diseases and combat hepatitis, water-borne diseases, and other communicable diseases
•
By 2030, reduce by a third premature mortality from non-communicable diseases through
prevention and treatment, and promote mental health and wellbeing
•
Strengthen the prevention and treatment of substance abuse, including narcotic drug
abuse and harmful use of alcohol
•
By 2020, halve the number of deaths and injuries from road traffic accidents globally
•
By 2030, ensure universal access to sexual and reproductive health-care services,
including for family planning, information, and education and ensure the integration
of reproductive health into national strategies and programmes
•
Achieve universal health coverage, including financial risk protection, access to
quality and essential health-care services, and access to safe, effective, quality,
and affordable essential medicines and vaccines for all
•
By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals
and air, water, and soil pollution and contamination
•
Strengthen the implementation of the WHO Framework Convention on Tobacco Control in
all countries, as appropriate
•
Support the research and development of vaccines and medicines for the communicable
and non-communicable diseases that primarily affect developing countries, provide
access to affordable essential medicines and vaccines, in accordance with the Doha
Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing
countries to use to the full the provisions in the Agreement on Trade-Related Aspects
of Intellectual Property Rights regarding flexibilities to protect public health,
and, in particular, provide access to medicines for all
•
Substantially increase health financing and the recruitment, development, training,
and retention of the health workforce in developing countries, especially in least
developed countries and small-island developing states
•
Strengthen the capacity of all countries, in particular developing countries, for
early warning, risk reduction, and management of national and global health risks
Decreasing prominence of health on the global political stage
Whereas health occupied three of the eight MDGs, health is specifically addressed
in only one of 17 SDGs and ten of 169 SDG targets. Effective measures to improve global
health outcomes draw on principles of international solidarity and shared responsibility,
recognising that all of us, irrespective of where we live, have a stake in improving
the health of our planet and its people. Yet growing hostility towards globalisation,
which has become especially pronounced in many countries that have long served as
global health donors, poses a potential threat to all forms of international and multilateral
cooperation, including global collaboration to address health and development challenges.
As threats to global solidarity have intensified, stresses on such multilateral institutions
as the European Union (EU) have become more apparent.
Substantial additional health investments will be necessary to achieve the SDG 3 targets.
Yet prospects for mobilising such sums appear in doubt as global assistance for health
has flattened since 2010.
13
Although domestic investments in health by LMICs have generally increased since 2000,
14
these investments frequently fall short of leaders' stated ambitions. In the Abuja
Declaration of 2001, African heads of state committed to allocate 15% of government
budget to health, yet most countries are not reaching this agreed benchmark.
15
Economic growth in LMICs (estimated at 3·9% in 2016
16
), if sustained, has the potential to expand the fiscal space for investments in health
if sufficient political commitment exists. However, most low-income countries will
for the foreseeable future lack the capacity to fully finance health and development
initiatives on their own, underscoring the continued need for robust and sustained
international assistance.
17
Weak and dysfunctional health systems and the future of global health
Health systems in much of the world appear unprepared to realise the vision of sustainable
health for all. As recently as 2013, 37 of 49 countries in Africa did not have a single
medical laboratory that satisfied international quality assurance standards.
18
In 2013, the number of health workers needed to provide essential health services
fell 17·4 million short of the number needed, with the most severe shortages occurring
in Africa and southeast Asia.
19
In Africa, health worker shortages are expected to worsen in the coming years.
19
Weak and overburdened health systems that are already struggling to provide basic
services will confront vastly more serious stresses in the coming years. The global
population is projected to grow from 7·6 billion people in 2017, to 9·8 billion people
by 2050, with the sharpest increase set to occur in Africa, where the population will
roughly triple in size.
20
Many health systems are unprepared to carry through on the SDG 3 target of reducing
NCD-associated premature mortality by a third. Although LMICs are home to 70% of global
cancer deaths, they account for only 5% of cancer spending worldwide.
21
Some countries in Africa have no clinical oncologists, whereas India reportedly had
only 29 treatment centres to manage cancer for more than 1 billion people in 2010.
22
Confronting the inherent inequities of the international order
The narrowing of economic disparities between rich and poor countries represents one
of the signal achievements of our era, but yawning inequities in access to resources
between countries and regions persist. In 2016, the per-capita gross domestic product
(GDP) in North America was more than 34 times higher than in south Asia or sub-Saharan
Africa and nearly 92 times higher than in low-income countries generally.
23
These extraordinary disparities in access to the fruits of the global economy are
inevitably reflected in health outcomes because lower socioeconomic status is closely
correlated with poorer health.
24
In addition to differences between countries, persistent social and economic inequalities
within countries increase vulnerability to disease and diminish service access. In
diverse countries, lower-income households consistently have poorer access to health
care than the more affluent and experience comparatively greater morbidity and mortality.
25
Existing global health mechanisms and practices fail to ensure ready, equitable access
to international public goods such as medicines and diagnostics. Although the 2001
Doha Declaration on TRIPS and Public Health recognised the flexibility of countries
under international law to obtain access to essential medicines, the global community
has yet to find a workable balance between trade and the right to health. Unfortunately,
the HIV response, which achieved a 99% reduction in the annual cost of first-line
ART between 2000 and 2015, largely remains an outlier with respect to medicines access
in resource-limited settings. Affordable diagnostic tools are also often in short
supply. Nearly half of African countries have no cancer radiotherapy services, leaving
four of five Africans without access to radiotherapy.
26
The 2014 Ebola outbreak in west Africa underscored the ongoing crisis of global health
governance.
27
Although the International Health Regulations were designed in part to discourage
restrictive and coercive responses to health emergencies, nearly a quarter of the
WHO member states imposed restrictions on trade and travel in response to the Ebola
outbreak.
28
WHO, a cornerstone for global health governance, remains chronically underfunded and
hobbled by a decentralised structure, which often inhibits rapid and effective responses
to emerging health crises.
29
Deteriorating environment for human rights, sound governance, and global cooperation
The underlying political and social environment is shifting in ways that are inimical
to good health and to the development of sound and sustainable health systems. After
years in which the proportion of the world's people living in free and democratic
societies increased, freedom is now in retreat, with one global freedom index reporting
the 11th consecutive year of decline in 2017.
30
Accompanying this democratic retreat is growing official hostility toward civil society
in many countries.
30
The increase in authoritarianism and the decrease in adherence to democratic norms
also risk normalising human rights violations and degrading universal human rights
commitments. The global retreat on human rights has exacted an especially heavy toll
on migrants and other disenfranchised groups. In 2015, the global population of displaced
people was greater than ever (21 million people) as raging conflicts in Syria and
elsewhere have compelled millions of people to flee their homeland.
31
More recently, government-sanctioned violence against the Rohingya minority in Myanmar
has caused hundreds of thousands of people to seek sanctuary in neighbouring countries.
Discriminatory practices within health systems, which frequently mirror prejudices
prevalent in the broader population, prevent many from accessing the most basic health
services. Migrants, indigenous populations, and ethnic minorities often encounter
hostility from health providers (including, in the case of migrants, formalised exclusion
of non-citizens from health-care services).
25
Lesbian, gay, bisexual, and transgender people worldwide experience considerable difficulties
in accessing good quality and non-judgmental health services.
32
Threats to planetary health
While political, social, and economic patterns threaten the foundation of global health,
continued deterioration of the physical environment potentially poses an existential
threat to the planet.
33
The planet is warming because of human activity, and failure to take swift action
to arrest or slow the growing concentration of manmade greenhouse gases is projected
to lead to further devastating increases in temperature in the coming decades. Threatening
the very habitability of our planet, these trends will have powerful effects on health,
affecting food production, susceptibility to heat-related illnesses and natural disasters,
and patterns for vector-borne and water-borne diseases.
The world's response to climate change in many respects serves as a fundamental test
case for international action to address shared threats. In this respect, recent trends
are not promising. In 2018, authoritative reports on climate trends indicated that
no developed country is on track to meet its pledges under the Paris Agreement and
that current warming trends suggest that the global temperature will rise in coming
decades well beyond the maximum threshold set by the Paris Agreement.
34
Towards sustainable health for all: a status report
As a result of remarkable increases in health spending,
35
the much healthier since 1990. Under-5 mortality decreased from 90 deaths per 1000
livebirths in 1990, to 43 deaths per 1000 livebirths in 2015, the proportion of children
younger than 5 years who are underweight decreased from 25% to 14%, and maternal mortality
decreased by 45% worldwide.
12
Adolescent mortality is estimated to have decreased by about 17% since 2000. Notable
reductions in the incidence of new infections and deaths associated with HIV, tuberculosis,
and malaria between 2000 and 2015 led the UN to declare that these epidemics had been
halted and reversed.
12
Globally, life expectancy increased faster in 2000–15 than in half a century, increasing
on average a full 5 years. The greatest increase in life expectancy occurred in Africa,
which had previously seen sharp reductions in life expectancy as a result of the HIV
epidemic (figure 2
). With three of the eight MDGs specifically focused on health, the MDG agenda catalysed
a remarkable increase in official development assistance for health.
Figure 2
Life expectancy in 2000 and 2016
Source: WHO.
An enormous gap persists between current reality and the vision of sustainable health
for all. Although numerous LMICs have made important strides in expanding health coverage,
36
400 million people do not have access to essential health services, and 6% of people
in LMICs are impoverished or pushed deeper into poverty by household medical expenses.
37
More than 15 000 children younger than 5 years die every day, largely from preventable
communicable diseases and malnutrition.
38
45% of childhood deaths are associated with undernutrition, 80% are associated with
low birthweight, and NCDs are increasing as a major cause of death in children.
39
In 2015, 1·2 million adolescents died, largely from preventable causes.
40
Adolescents are at high risk of sexually transmitted infections (including HIV
41
), unintended pregnancy, unmet contraceptive need, and contraceptive failure.
42
NCDs (eg, cancers, cardiovascular disease, hypertension, and diabetes) account for
70% of deaths worldwide, and more than 75% of NCD-related deaths occur in LMICs.
43
In the future, LMICs will account for up to 80% of the anticipated global increase
in cancer cases and deaths.
44
NCDs are projected to exact economic costs of $47 trillion in the next two decades,
45
and progress in combatting NCDs will affect the world's ability to attain at least
nine of the 17 SDGs.
46
While the world mobilises to address NCDs as the primary driver of mortality and disability,
the global community must follow through on its commitments to make communicable diseases
a thing of the past. Tuberculosis, for example, is the leading cause of death by single
infectious agents, the ninth leading cause of death overall (accounting for 1·7 million
deaths in 2016
38
), and the leading cause of death in people living with HIV.
47
Africa accounts for roughly 80% of all cases of and death from combined HIV and tuberculosis.
Unlike HIV, tuberculosis is a curable infection. Nearly half of the world's population
is at risk for malaria, and no meaningful progress in reducing malaria cases and deaths
was seen in 2016.
48
Likewise, the challenge of addressing viral hepatitis remains considerable (figure
3
). An estimated 71 million people worldwide have chronic hepatitis C virus (HCV) infection,
and 2·7 million of these people have HIV infection.
51
An estimated 1·34 million people die from viral hepatitis each year, and this includes
an estimated 399 000 deaths related to HCV infection.
51
Figure 3
Global burden of hepatitis B virus and hepatitis C virus
(A) Prevalence of hepatitis B virus infection between 1957 and 2013. (B) Prevalence
of anti-hepatitis C virus between 1990 and 2013. Adapted from Schweitzer et al (2015)
49
and from Gower et al (2014),
50
by permission of Elsevier.
Alcohol and drug use disorders are associated with extensive morbidity, disability,
and mortality
52
and are also closely linked with HIV transmission through the sharing of syringes
and the effects of specific drugs (eg, amphetamines) on condom use and sexual HIV
transmission.
53
In 2016, mental health disorders accounted for nearly 16% of years lived with disability
worldwide.
52
HIV and global health: what have we learned, and where do we go from here?
The global HIV response serves as one of the most inspiring undertakings in the history
of global health. The escalating toll of AIDS across the world in the 1980s and 1990s,
especially in sub-Saharan Africa, resulted in “the single greatest reversal in human
development” in history.
54
However, a genuinely multisectoral and multidimensional global mobilisation uniting
and synergising a diverse set of actors from all across the world achieved what some
considered unattainable: halting and beginning to reverse the epidemic.
55
These health advances have had profoundly positive effects on households, communities,
and societies. In South Africa, home to nearly one in five people living with HIV,
sharply reduced AIDS-related mortality stemming from a remarkable expansion of HIV
treatment services caused average life expectancy to increase from 52 years to 61
years in less than a decade.
56
An unprecedented expansion of access to ART
The greatest achievement of the HIV response to date has been the unprecedented global
expansion of access to ART. Although only 680 000 people were receiving ART in 2000
(most of them in high-income countries), by June 2017, this number had risen to 20·9
million people (18·4 million–21·7 million), or 57% of all people living with HIV worldwide.
57
In 2016, an estimated 1·6 million deaths were averted worldwide as a result of ART.
1
The history of ART and its effect on the global HIV epidemic is one of multidisciplinary
collaboration, continual improvements in the quality and durability of treatment regimens,
ever-increasing aspirations for service coverage, and passionate advocacy to overcome
the resistance that HIV treatment expansion elicited. Public and private sector researchers
combined to generate the therapies capable of halting viral replication; civil society
advocacy and competition from and within the generic pharmaceutical industry coalesced
to produce marked reductions in the prices of ART; robust funding, primarily at the
outset from international donors, enabled rapid introduction and expansion of treatment
programmes; and programme planners and implementers (as well as affected communities)
have helped to improve the efficiency and effectiveness of HIV treatment service delivery.
As the scientific evidence expanded, normative guidance on HIV treatment evolved,
and in 2015, WHO recommended the initiation of ART for all people living with HIV,
irrespective of disease stage, both for clinical benefit to the individual living
with HIV and for the prevention benefits of successful viral suppression on onward
transmission.
58
Substantial scientific advances have also been achieved in primary HIV prevention.
Principally due to implementation of ART for pregnant women and other measures to
prevent vertical HIV transmission, the number of children newly infected with HIV
decreased from 470 000 children in 2002, to 160 000 children in 2016.
1
Since results of clinical trials more than a decade ago showed that medical male circumcision
reduces the risk of female-to-male sexual HIV transmission by about 60%,
59
nearly 15 million men in sub-Saharan Africa have been circumcised.
60
PrEP has substantial HIV prevention efficacy,
61
and cash transfers might reduce young people's HIV risk behaviours or the odds of
acquiring HIV, or both.
62
The future of HIV: an unfinished agenda with an uncertain outcome
The fight against HIV is far from over. In eastern Europe and central Asia, the incidence
of new HIV infections increased by 60% between 2010 and 2016,
5
and the incidence is also trending upwards in populous countries such as Philippines
and Ghana.
1
Progress in reducing new HIV infections in adults has largely stalled worldwide. Although
UNAIDS estimates that new HIV infections in adults decreased by a modest 11% between
2010 and 2016,
5
the Global Burden of Disease Study 2015 investigators found no meaningful decrease
in new HIV infections in the previous decade.
8
The coming demographic wave, as children become adolescents and young adults, threatens
major expansions of the epidemic. In 2016, 43% of the population in low-income countries,
43% of the population in all of sub-Saharan Africa (excluding high-income countries),
and 31% of the population in lower-middle income countries were younger than 15 years.
63
In a recent modelling study, the failure to build on existing prevention and treatment
coverage gains was found to result in a rebound of the HIV epidemic in the coming
years.
64
The 90-90-90 approach: its promise and its limitations
As part of the SDGs, UN member states have pledged to end the AIDS epidemic as a public
health threat by 2030, which has been defined as reducing the number of new HIV infections
and AIDS-related deaths by 90% relative to 2010. The cornerstone of this global undertaking
is the UNAIDS 90-90-90 approach, which follows that by 2020, 90% of all people living
with HIV will know their HIV status, 90% of people with an HIV diagnosis will receive
ART, and 90% of people receiving ART will achieve viral suppression.
65
The 90-90-90 approach is grounded in the considerable evidence that ART sharply reduces
the risk of HIV transmission.
66
Within the Fast-Track strategy proposed by UNAIDS to reduce the incidence of new HIV
infections to less than 200 000 annually by 2030, UNAIDS estimates that scaled-up
ART will account for 60% of HIV infections averted during this period.
64
However, it is increasingly clear that the 90-90-90 approach on its own will be inadequate
to end the epidemic. Even as ART coverage has steadily increased and as the HIV response
has adopted an almost singular focus on HIV treatment expansion, the rate at which
the incidence of new HIV infections is decreasing remains far too slow to achieve
epidemic control. A case in point is Botswana, which might already have achieved the
90-90-90 target,
67
but the decrease in new HIV infections is far too modest to end the country's epidemic.
1
Outcomes across the HIV treatment continuum in eastern and southern Africa, Latin
America, and high-income countries are cause for optimism that the 90-90-90 target
might be achieved by 2020 in these settings (figure 4
). However, in other regions, the proportion of people living with HIV who had suppressed
virus in 2016 was far off the pace for the 73% target viral suppression benchmark
for 2020 under the 90-90-90 approach (viral suppression was achieved for 34% of people
with HIV in the Caribbean, 25% in west and central Africa, 22% in eastern Europe and
central Asia, and 16% in the Middle East and north Africa).
1
Ensuring widespread viral suppression is also a challenge in many high-income countries
such as the USA, where only 49% of people with HIV were virally suppressed in 2014.
68
Figure 4
Knowledge of HIV status, treatment coverage, and viral load suppression by region
in 2016
Comparison of HIV testing and treatment cascades by region reveals different patterns
of progress. Western and central Europe and North America are approaching global targets.
Latin America and eastern and southern Africa show high levels of achievement across
the cascade. Eastern Europe and central Asia, the Middle East and North Africa, and
western and central Africa are clearly off track. Source: UNAIDS special analysis,
2017.
The prevention benefits of expanded ART would be substantially enhanced by a similarly
vigorous scale-up of other strategic prevention interventions. In Uganda, the combination
of steady expansion in ART coverage, a near-doubling of the rate with which HIV viral
suppression is achieved, and roll-out of medical male circumcision was associated
with a 42% reduction in HIV incidence in 10 years.
69
In cities in high-income countries, the prioritised roll-out of PrEP as a complement
to the test-and-treat approach has contributed to sharp decreases in the incidence
of new HIV infections, especially in gay and bisexual men.70, 71 Although the so-called
combination prevention approach has long been recommended as the optimal means to
reduce the risk of new HIV infections, the approach has seldom been implemented at
scale because national HIV responses have increasingly come to be dominated by an
overwhelming emphasis on HIV treatment. Less than one in five people at risk of HIV
acquisition have access to prevention programmes because of chronic underfunding of
HIV prevention.
6
An alternative future for the HIV epidemic: persistent settings and communities with
heavy HIV burdens
Far from putting the world on course to vanquish AIDS, existing approaches are leaving
numerous populations behind. In sub-Saharan Africa, young people and men of all ages
consistently have suboptimal outcomes along the HIV treatment continuum.
5
Various marginalised populations at increased risk of HIV infection, including gay
and bisexual men, people who inject drugs, sex workers, transgender people, and the
sex partners of people in these groups, accounted for 44% of new HIV infections worldwide
(80% of new infections outside sub-Saharan Africa).
5
Contrary to optimistic expectations of ending AIDS, these trends point toward the
likelihood of a much more concerning scenario. Athough the desired benefits of population-level
viral suppression could be realised in settings and populations where access to HIV
testing and treatment services is widespread, those people living in countries or
belonging to marginalised populations in which services are difficult or impossible
to obtain will remain highly vulnerable to HIV acquisition.
Already, evidence suggests that the epidemic is sustained in substantial high-prevalence
and high-incidence geographical areas in large measure by the inability of service
systems to reach and engage specific populations. For example, even as the incidence
of HIV infections in the USA have decreased overall since 2008,
72
black gay and bisexual men now have a 50% lifetime chance of acquiring HIV (figure
5
).
73
Rates of viral suppression in people living with HIV in the USA have steadily improved,
74
but black gay and bisexual men living with HIV are markedly less likely than other
people living with HIV to receive ART, remain engaged in care, and achieve viral suppression.
75
Major pockets of endemic HIV are also apparent in Russia, where HIV infections are
heavily concentrated in six subnational regions (referred to as Federal Subjects)
in eastern and western Siberia, along principal overland heroin and opium trafficking
routes out of Afghanistan. In the case of people who inject drugs, in Russia and elsewhere,
access to prevention and treatment services is extremely limited.
76
A similar clustering of susceptibility to HIV is apparent in the KwaZulu-Natal province
of South Africa, where adolescent girls and women younger than 25 years are roughly
three times more likely than men younger than 25 years to be living with HIV.
77
Figure 5
African American men who have sex with men have an increased lifetime acquisition
probability of HIV infection in 2018
Credit: © NASTAD.
The persistence of large, high-prevalence, and high-incidence areas in the midst of
epidemics that are large and small, decreasing and increasing, is a global phenomenon.
Compared with the population as a whole, gay men and other men who have sex with men
(MSM), people who inject drugs, sex workers, and transgender women are 19 times,
78
13·5 times,
79
22 times,
80
and 49 times,
81
more likely to be living with HIV, respectively. Yet although these marginalised populations
have a disproportionate and growing HIV burden, they are often the groups least likely
to obtain access to HIV prevention, treatment, and care services.
78
With the failure of existing service approaches to address persistent susceptibility
or to reach those people who are in greatest need, it is clear that new and scaled-up
service delivery and community engagement stra-tegies will be needed. The transmission-preventing
potential of scaled-up ART must be matched with an equally strong reduction in the
risk of HIV acquisition and transmission.7, 82 And programmes for the delivery of
prevention and treatment services must be coupled with renewed efforts to address
the social and structural factors that increase risk and susceptibility and diminish
utilisation of essential services.
Activism and the future of the HIV response
Grassroots political activists have had a defining role in the HIV response. In the
epidemic's early years, gay communities in several countries mobilised to resist the
imposition of coercive measures in what was then a new and frightening epidemic. Across
the world, chapters of the AIDS Coalition to Unleash Power (ACT UP) marched in the
streets and infiltrated decision making bodies to demand greater investments in HIV
research and expedited, people-centred approaches to the evaluation and approval of
new medicines. In South Africa, activism by Treatment Action Campaign and other groups
led to dramatic changes in national HIV policies, which have reverberated around the
world. In every region, activists have emerged to challenge high prices for HIV treatments
and to insist on approaches to intellectual property that take into account the needs
of people with life-threatening diseases.
Today, inclusion of civil society and people living with HIV is standard practice
of many HIV-related decision making bodies. Non-governmental representatives, including
from organisations and networks of people living with HIV, are now routinely involved
in national HIV-related advisory bodies. Vigorous activism persists in many countries
and regions. However, as the incidence of HIV infections and AIDS-related mortality
have decreased, and as funding for civil society activities has diminished, so have
the magnitude and intensity of AIDS activism. In particular, the kind of cohesive
activist voice that united the global north and south and laid the foundation for
the HIV treatment revolution is no longer evident. In some cases, experiences in the
HIV response have led some activists to concentrate more on broader health and human
rights issues. For some, a focus on service delivery in their own communities has
taken the place of activism for systemic change.
Standard inclusion of civil society in national and global bodies is one of the great
achievements of the HIV response and one of its defining features, yet the voices
of grassroots activists are at risk of being silenced or muffled. As a class of international
and non-governmental HIV professionals has developed, questions have emerged about
a potential disconnect between civil society spokespeople at the global level and
those working in communities. The inclusion of civil society in decision-making bodies,
especially at the global level, is often more tokenistic than substantive.
How to rejuvenate and empower a new wave of activism on HIV remains a topic of considerable
discussion and debate within the HIV community (figure 6
). What is clear is that the loss of a strong activist presence diminishes both the
accountability of the HIV response and the likelihood that our policies, programmes,
and approaches will respond to the communities being left behind. Few advocacy community
equivalents to HIV exist in other domains of global health. Infusing the broader global
health field with the grassroots energy and leadership that has defined the HIV response
could revolutionise global health and elevate it on the global political agenda, but
a key first step towards this end is to reinvigorate HIV activism.
Figure 6
Activism on HIV in India
Students recognise International AIDS Candlelight Memorial Day with painted faces
at the Centre for Social Work, Panjab University, Chandigarh, India. Credit: © 2016
Gaurav Gaur, Photoshare.
The future of HIV exceptionalism
From the earliest recognition of the epidemic in the early 1980s, the HIV response
adopted an exceptionalist approach. Rather than look to often-overburdened health
systems to manage HIV as one of many health problems, specific vertical funding mechanisms
and frequently disease-specific service delivery channels were established to respond
to the global emergency. In 2000–01, diverse global stakeholders spearheaded the creation
of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which, by the end of 2016,
had allocated more than $17 billion for HIV programmes in more than 100 countries,
while also providing much needed support to chronically neglected tuberculosis and
malaria.
83
Created in 2003, the US President's Emergency Plan for AIDS Relief (PEPFAR) is the
largest bilateral health programme ever devoted to a single disease. The UN also took
a distinctly unorthodox approach to HIV, vesting UN leadership on the epidemic, not
with the designated health agency WHO, but in the Joint United Nations Programme on
HIV/AIDS (UNAIDS), a multidisciplinary and cosponsored programme.
84
Whether such an exceptionalist approach will remain feasible is unclear. Overall investments
in the HIV response, taking into account both domestic and international sources,
has remained relatively flat in recent years, at about $19·1 billion, roughly $7 billion
short of the amounts needed to achieve 90-90-90 and the broader UNAIDS Fast-Track
strategy.
5
In 2016, total resources for HIV programmes actually decreased by 7%.
85
In the midst of growing insecurity and disorder in the regions that have historically
led in mobilising international financing for the HIV response (namely, North America
and Europe), HIV seems less frightening than in earlier times. African leadership
in the HIV response, so crucial to success under the MDGs, is also less visible. In
a globalised world where attention spans are limited, the temptation to pretend that
HIV is a problem that has been solved has proven to be powerful.
As the HIV response grapples with an uncertain future and works to identify optimal
strategies for sustainability, it faces a pivotal challenge in defining, for the long-term,
its relationship to the global health field. Appropriately integrating HIV within
broader health systems will probably be essential to achieve ambitious global HIV
aims, sustain treatment access in decades to come, and spread costs associated with
controlling the epidemic. However, there are genuine risks to wholesale relinquishment
of the exceptionalist approach to HIV. Notwithstanding the many criticisms of vertical
health programmes, there is little dispute that HIV exceptionalism has worked, mobilising
extraordinary new financial, technical, and human resources, uniting diverse stakeholders,
focusing global attention on concrete results, driving and benefiting from scientific
innovation, and engaging communities in far-reaching ways. Abandonment of an approach
that has been groundbreaking in its success should not be done without a rigorous
interrogation of the risks and benefits of mainstreaming the HIV response into national
health systems.
Heeding the lessons of the HIV response
Even as the HIV response will inevitably depend on health and social systems to achieve
its ambitious global target for 2030, lessons from the HIV response are also instructive
for the future of global health. The UNAIDS-Lancet Commission on Defeating AIDS—Advancing
Global Health in 2015 outlined the salient attributes of the HIV response that have
contributed to its success and that should inform broader global health efforts. These
include the sustained leadership of civil society and people living with HIV, the
multistakeholder nature of the response, the extraordinary degree of political leadership
for the fight against HIV, the centrality of human rights, gender equity, and social
justice to the response, and a commitment to global and local-level accountability
and transparency.
6
Similarly pivotal has been the close link between scientific research and efforts
to strengthen HIV programmatic efforts.
An emphasis on innovation has typified the HIV response from its earliest days and
is in large measure responsible for bringing the world to the point where HIV as a
medical problem can be effectively managed. Continuing research investments have made
possible first-line HIV treatment regimens that are more durable, more tolerable,
and less expensive than the regimens that have already saved millions of lives. Additional
innovations that are anticipated in the coming years, including long-acting antiretroviral
regimens for both HIV treatment and PrEP, are among the reasons for optimism that
even greater progress against HIV is achievable in the coming years, including the
ultimate goals of a preventive vaccine and a functional cure for HIV.
Infusing the HIV response with a renewed energy and sense of purpose will be challenging,
but the future health and wellbeing of countless millions of people require that we
meet this challenge. Decision makers must be made aware of the profound and indisputable
humanitarian and economic stakes at play in the future of the HIV epidemic. While
fully acknowledging the daunting challenges we face, the HIV community must reinvigorate
itself and embrace the scientist–activist zeal that yielded such historic achievements.
Opportunities for integration and synergy in the global health and HIV responses
Linking global health and HIV responses more closely and integrally across health
programmes and practice is hardly a new idea. Experience in integrating HIV in broader
health systems underscores both the benefits and potential risks associated with a
more integrated and less exceptionalist approach to HIV, illustrates the challenges
confronting greater linkage and integration, and highlights potentially valuable opportunities
to rethink further how the HIV response fits within the broader global health enterprise.
This experience further shows that the options for future programmatic approaches
to HIV are not confined to a binary choice between exceptionalism or wholesale integration,
but rather that several opportunities exist in the immediate-term for more incremental
integration and for learning by doing. In all cases, steps toward integration should
be undertaken thoughtfully, retaining the key principles that have defined the HIV
response.
People and communities
To advance the SDGs' goal of leaving no one behind and addressing the needs of the
most susceptible first, innovative and rights-based approaches are needed to realise
the vision of sustainable health for all. The particular health needs of different
populations, outlined here, illustrate diverse ways in which the HIV response and
the global health field can benefit and learn from each other.
Children's health: ensuring that every child has the best chance at healthy adulthood
Comparatively well funded and vertical disease programmes have had a clear effect
on child health. Childhood vaccination programmes, including programmes supported
by GAVI, the Vaccine Alliance, have generated exceptionally high and increasing rates
of immunisation.
39
Between 2000 and 2014, measles vaccination is estimated to have saved 17·1 million
lives.
86
Between 2010 to 2015, the mortality from malaria in children younger than 5 years
decreased by 35%
87
because of dramatic increases in the coverage of key malaria interventions.
39
The HIV response illustrates both the potential of focused global action to improve
the health of children as well as the persistent failures of health systems to address
children's needs. As the proportion of pregnant women living with HIV who receive
antiretroviral medicines has increased, the incidence of new HIV infections in children
has sharply decreased. In 2016, the 160 000 new HIV infections in children represented
a 47% decrease since 2010, and a 66% decrease since 2005.
1
By contrast, little progress has been made with respect to integrated interventions
that rely on regular contacts with the health system. Comparing utilisation data for
2000–08 with that of 2009–14, met demand for family planning services increased only
modestly, from 54% to 64%, the proportion of pregnant women who visited antenatal
care at least four times increased only from 50% to 56%, the share of births with
a skilled attendant increased only incrementally, from 55% to 65%, and similarly modest
increases (less than 10%) were reported for exclusive breastfeeding, oral rehydration
therapy, and care-seeking for pneumonia.
39
Shortcomings in health systems that undermine health outcomes for children include
weak laboratory systems, inadequate systems for monitoring mother–child pairs from
antenatal to paediatric care settings, fragmented service delivery systems that invite
discontinuity of care, and frequent drug stock-outs.
These deficiencies in health systems are evident with respect to HIV treatment for
children. HIV treatment coverage in children (46% as of June, 2017) remains far lower
than in adults (58%), resulting in notably higher morbidity and mortality in children
than in adults.
1
Although children accounted for 6% of all people living with HIV worldwide in 2016,
they made up 12% of all AIDS-related deaths.
1
The persistent coverage gap between children and adults has long been excused by complexities
associated with diagnosing and treating HIV in children, including the need for virological
testing to confirm HIV infection in children and the historic shortage of child-appropriate
antiretroviral reformulations. However, as a result of technological advances in recent
years, the means to address these complexities now include point-of-care early infant
diagnostic testing platforms, innovative methods to reduce turnaround times for standard
virological testing by remote central laboratories, and striking progress in optimising
treatment options for children.
Effectively integrating service delivery for children will meet children's health
needs in a holistic manner and provide co-located services that are effective, efficient,
and of good quality. Health-service integration for children spans not only the levels
of care (eg, community, primary, and referral) but also the child's life (pre-pregnancy
to childhood). The Global Action Plan for the Prevention and Control of Pneumonia
is a valuable approach to service integration, providing a framework for coordinated
and integrated actions to improve feeding and nutrition for infants and young children,
access to safe drinking water and sanitation, hand washing with soap, reduction in
indoor air pollution, immunisation, HIV prevention, and treatment of pneumonia and
diarrhoea.
88
Adolescent health
Health risks are especially acute for adolescent girls (figure 7
). The risk of new HIV infections in women living in high-burden countries in sub-Saharan
Africa peaks at age 15–24 years, about 10 years earlier than in their male peers,
and AIDS persists as the fourth leading cause of death in adolescent girls and young
women in sub-Saharan Africa.
89
The disproportionate health burden in adolescent girls stems from a confluence of
factors, including the persistently low socioeconomic status of women in many societies,
lack of educational and economic opportunities, and sharply limited access to family
planning and adolescent-friendly health services.
Figure 7
Sexual and emotional health in adolescents in India
A young girl attends a candlelit march for sexual and emotional health for young teens
in Udaipur, India. Credit: © 2016 Arvind Jodha/UNFPA, Photoshare.
One in four women worldwide become married before age 19 years, and 6% of women are
married before age 15 years.
90
Early marriage is linked with lower nutritional status, lower educational attainment,
increased mortality for women,
91
increased risk of HIV acquisition,
92
intimate partner violence,
93
and reduced health, nutritional status, and socioeconomic outcomes for their children.
91
Particular risks are experienced by the estimated 21 million girls aged 15–19 years
and the 2 million girls younger than 15 years who give birth each year.
94
Pregnancy during adolescence increases the risk of complications, and childbirth is
the leading cause of death in girls aged 15–19 years.
91
Giving birth during adolescence also increases health risks for newborn children,
including low birthweight, preterm delivery, and poor long-term developmental outcomes.
95
Minimising health risks for adolescent girls, including but not limited to HIV infection,
will rely on an unprecedented, well resourced, and multisectoral effort. Keeping girls
in school, through cash transfers and other strategies, is an overriding priority.
The HIV response has galvanised interdisciplinary work to clarify young people's reasons
for engaging in unprotected sex and effective means to reduce sexual risks. Data from
extensive research have conclusively shown that abstinence is a failed strategy for
HIV prevention.
96
Effective prevention of HIV and sexually transmitted infections and advancement of
broader sexual and reproductive health in young people necessitates evidence-based,
tailored, flexible, and client-centred approaches to sexual harm reduction and comprehensive
sexual education (figure 8
).
97
Ready access to contraception and other family planning services is essential because
half of pregnancies in girls aged 15–19 years are unintended.
98
Figure 8
HIV testing, family planning education and referrals, and deworming kits in Uganda
A dance troupe with Public Health Ambassadors Uganda perform in the Kasana Market
in Luwero to call attention to a pop-up health clinic providing HIV testing, family
planning education and referrals, and deworming kits. Credit: © 2016 David Alexander,
Photoshare.
Changing lifestyles mean that an increasing number of adolescents are susceptible
to the health risks associated with poor diet, tobacco, alcohol and substance abuse,
malnutrition (including anaemia and obesity), and NCDs such as diabetes and cancer.
In turn, these risks are associated with preventable mortality in adulthood. Mental
health issues are among the top five causes of adolescent disability-adjusted life-years
(DALYs) lost, with more than 75% of mental illnesses originating before age 24 years.
99
All adolescents have the right to accessible health services. Helping youth to prioritise
health and engage in services is challenging when low mortality and good health is
expected in young people, prior experience in health-care interaction is limited,
and concern about confidentiality breaches is high.
99
Among the key lessons learned in the HIV response is that health services must be
tailored to young people's needs and preferences and should offer an integrated combination
of services. Integrated service packages must include comprehensive health checks
relevant to adolescents and take into consideration other priorities such as education
and economic opportunities, which, if unaddressed, lead to poor health and wellbeing.
89
Achieving universal health coverage demands the availability of adolescent-focused
health services in all health facilities and in other more accessible multipurpose
spaces. Adolescent-friendly services offer operating hours outside of work or school,
create a friendly and non-judgmental environment, engage peers in support functions,
promote health in ways that appeal to young people, and use modern technologies and
innovations already incorporated in the daily lives of adolescents.100, 101
Meeting the needs of women
Women's health needs often differ from those of men. Whereas breast cancer is not
a leading cause of death in men, the breast is the most common site of cancer diagnosis
in women (accounting for 25% of all cases in 2012).
44
Cervical cancer is the fourth leading cancer diagnosis in women and the fourth leading
cancer-related cause of death in women.
44
Although maternal mortality has decreased, an estimated 830 women die daily from preventable
causes associated with pregnancy and childbirth.
102
In addition to heightened physiological vulnerabilities to many diseases and health
conditions, women's health risks are often closely linked with their unequal status
in societies. For example, an estimated one in three women worldwide will experience
physical or sexual violence, and those women who do are roughly twice more likely
to experience depression or have an alcohol use disorder and 16% more likely to have
a baby with low birthweight than those women who do not.
103
Because of both increased physiological susceptibility to HIV acquisition during penile–vaginal
intercourse and because of gender-related challenges in negotiating safer sex, women
are especially susceptible to HIV, accounting for 56% of all people living with HIV
in sub-Saharan Africa.
1
Women's experience of intimate partner violence has been correlated with a 50% increase
in the risk of HIV acquisition,
104
and emotional abuse by partners is linked with rapid progression of HIV disease in
women.
105
The HIV response has long joined forces with the broader women's health agenda through
political advocacy for gender equality, programmes to promote healthy gender norms,
and strategies to prevent gender-based violence. At national, regional, and global
levels, women living with HIV have organised networks to provide mutual support and
to increase recognition of HIV as a women's health issue. Substantial resources have
been invested in condom programming and other interventions to reduce women's sexual
risks and in research to develop prevention methods that women can control on their
own.
The successful global scale-up of ART in women has shown the feasibility of achieving
broad access to care for women. Among people living with HIV, women are more likely
than men to know their HIV status, receive ART, and achieve viral suppression.
5
The proportion of pregnant women living with HIV who receive effective antiretroviral
medicines increased from 47% in 2010, to 76% in 2016.
5
There is growing recognition that the women's health agenda must move beyond its traditional
focus on sexual and reproductive health and tackle women's growing burden of NCDs.
105
The Pink Ribbon Red Ribbon partnership, working in six countries in sub-Saharan Africa
and Latin America, aims to leverage momentum and infrastructure from the HIV response
to reduce the cancer burden in women. Through the third quarter of 2017, the partnership
reported that it had screened more than 465 000 women for cervical cancer and more
than 34 000 women for breast cancer, administered the vaccine for human papillomavirus
to nearly 148 000 girls, and provided treatment services to almost 30 000 women diagnosed
with cervical cancer.
106
The gender gap in health: services for men
Health outcomes are consistently worse in men than in women. In 2015, mean life expectancy
was 5·8 years higher in women than in men (74·8 years [uncertainty interval 74·4–75·2]
for women vs 69·0 [68·6–69·4] for men), and this gender gap in life expectancy is
increasing over time.
107
These patterns are vividly reflected in HIV-related outcomes; in 2016, men accounted
for less than half of all adults (>15 years) living with HIV but for an estimated
58·4% of AIDS-related deaths.
1
A key driver in gender differences in health outcomes appears to be men's comparatively
lower utilisation of health services. In a national survey in 2013,
108
men in the USA were markedly less likely than women (72% vs 86%) to report a regular
source of care or to report having seen a health-care provider in the previous 2 years
(75% vs 91%). Across regions, men are consistently less likely than women to know
their HIV status, to receive ART, and to remain engaged in care once they initiate
HIV treatment.
5
In many countries, especially in LMICs, the best developed health-service delivery
platforms (eg, antenatal, maternal, paediatric, sexual and reproductive services)
are often designed primarily for use by women or children, or both. In many settings,
few, if any, health-service delivery channels have been developed specifically with
men in mind. This has led to the common belief that clinics are not meant for men,
109
deterring men from accessing health services. Often, health services are accessible
only during working hours, further discouraging male workforce participants from obtaining
the services they need. Popular notions of masculinity might also disfavour receipt
of health services as a sign of weakness.
110
In view of the severe gender gap in health, it is striking how little attention the
HIV response or the global health field has given to men's health issues. To close
the gender gap, decision makers must expressly value men's lives and prioritise action
to increase men's access to and use of health services. In the case of HIV, a growing
body of evidence suggests that community-centred programmes that specifically work
to engage men and address their needs and preferences (including flexible clinic hours,
mobile services, workplace programmes, and private access) can effectively diminish
the gender gap in men's utilisation of health services.
111
To reach nearly 15 million men with voluntary medical male circumcision in 14 African
countries in 2008–16, and thereby avert more than 500 000 new HIV infections through
2030,
60
circumcision programmes worked with men and local communities to forge new social
norms, offered services at hours that corresponded to men's needs, used a variety
of service delivery approaches (eg, mobile outreach), and integrated circumcision
services with multiple other health services.
112
Innovative service models could diminish or eliminate gender gaps in HIV service utilisation
(figure 9
). SEARCH, a community-centred research project in 32 rural communities in Kenya and
Uganda, integrated HIV testing in multidisease health fairs and used innovative approaches
to deliver ART through co-located services. To help avoid a gender gap in testing
utilisation, SEARCH created men-only discussion groups that invited men to discuss
HIV and sexual health issues. After 2 years of the intervention, gender gaps across
the 90-90-90 cascade had effectively disappeared, with men achieving the first two
90s and 88% viral suppression.
113
Figure 9
HIV testing services in Kenya
A counsellor provides HIV testing services to livestock herders during community outreach
services in the Eremit area of Kajiado County, Kenya. Credit: © 2012 George N Obanyi/FHI
360, Photoshare.
People who inject drugs
One of the great ironies with respect to the prohibitionist approach to substance
use, which treats drug use primarily as a law enforcement and national security matter
and continues to have widespread and negative implications for HIV
114
and global health more generally, is that it was initiated in the name of public health.
A further irony is that these failed policies also spawned one of the most successful
of all HIV prevention strategies. Harm reduction is a practical and rights-based approach
that aims to mitigate the negative consequences of behaviours, including when cessation
of the behaviour is infeasible or not desired by the individual. This approach has
potential applicability to a host of health problems beyond blood-borne pathogens
such as reducing alcohol-related problems, minimising road trauma, and preventing
skin cancers. Harm reduction needs be seen as a core global health promotion strategy.
For prevention of HIV and viral hepatitis, harm reduction has traditionally referred
to a range of services that include the provision of clean needles and syringes (NSPs).
Combined with access to medication-assisted therapy (MAT), NSPs continue to be the
most effective strategy to reduce new HIV infections in people who inject drugs. Harm-reduction
services have the added public health benefit of facilitating linkages to other HIV-related
services, drug treatment, and primary health care. Harm reduction is increasingly
being adopted in diverse settings, although large gaps in the scale and coverage of
harm-reduction programmes limit the ability of many countries to halt HIV and HCV
epidemics.
115
The USA, long a leading proponent of the global war on drugs, appears poised to undertake
a rapid expansion of MAT in response to a surge in opioid addiction, offering potential
opportunities to alter the global discourse on harm reduction.
To reduce the negative consequences associated with drug use, expansion of harm-reduction
services also needs to be coupled with broad-based reform of laws and policies. Incremental
progress has been made in reforming UN drug conventions to incorporate certain health
and human rights considerations, but a wholesale paradigm shift in the global approach
to drug use has yet to occur.
116
Needed legal reforms (eg, decriminalisation, proportional sentencing, or diversion
to health and social services for non-violent offenders) will not only facilitate
greater access to health and social services for susceptible communities but also
sharply reduce prison populations. Reductions in the prison population might free
up resources for scaling up ART, drug treatment, and primary health care in prison
settings and reduce the incidence and risk of infectious diseases. In pursuing locally
tailored drug policy reform, nation states and states within nation states can help
build a compelling evidence base that can guide and inform reform efforts, unlock
new efficiencies in prison systems, and build new constituencies for drug policy reform.
To transcend polarising political debates that have limited its support, harm reduction
itself needs to expand and mainstream its ethos and more integrate its application
beyond drug use across a wider spectrum of stakeholders and public health issues.
Gay and bisexual men
In 2016, 12% of all new HIV infections worldwide and 22% of all incident infections
outside sub-Saharan Africa were in gay men and other MSM.
117
Among HIV risk behaviours, HIV acquisition from condomless and receptive anal intercourse
is twice more likely than from needle sharing during injecting drug use and more than
17 times more likely than from receptive penile-vaginal intercourse.
118
However, gay men's disproportionate HIV burden cannot be disentangled from their profound
(and in many settings, worsening) social disadvantages. In 2017, more than 70 countries
criminalised consensual same-sex relations,
119
and the legal and policy barriers confronted by gay men have only increased in recent
years, including through enactment of Russia's so-called gay propaganda law and a
draconian anti-gay law in Nigeria that went into effect in 2014. The past 2 years
witnessed a sharp increase in the number of arrests of gay men in Indonesia
120
and the forced closure of drop-in clinics providing HIV and other health and social
services to gay men in Tanzania.
121
Such a climate of fear and hostility inevitably increases gay men's susceptibility
to HIV and reduces their access to essential prevention and treatment services. In
India and in Moscow, only a small minority of gay men living with HIV have achieved
viral suppression, with lack of knowledge of HIV status serving as the most serious
service bottleneck.122, 123 Coverage of PrEP, a potentially transformative prevention
tool for gay man and other marginalised populations, is only minimal outside of high-income
countries.
5
A crucial barrier to a more effective HIV response for gay men (and an unfortunate
reflection of the neglect of gay men's needs) is the shortage of robust evidence for
action in this population. Although findings from focused studies continue to demonstrate
extraordinarily high HIV prevalence and incidence in gay men in broadly diverse settings,
evidence on gay men from standard surveillance systems is extremely limited, primarily
because these systems focus on adults of reproductive age, especially in high-burden
settings. Many countries still have no estimates of the size of the gay population,
and half of those countries with estimations employ methodologies that call the reliability
of these estimates into question.
124
Migrants and the displaced
The number of people living in a country other than the one in which they were born
(244 million in 2015) is larger than the population of all but four countries.
125
In addition to cross-border migration, many people move for work or other reasons
to different states or provinces within their own country; In China alone, this affects
more than 280 million rural migrants.
126
Worldwide, the migrant population includes 65·6 million forcibly displaced people,
22·5 million refugees, and 10 million stateless people.
127
Addressing the health needs of the world's massive and growing population of migrants
is a health and human rights imperative.
128
However, public health insurance schemes often exclude or limit services for migrants,
especially for those who are undocumented. In part through regional cooperative compacts,
more countries are taking steps to introduce health insurance approaches that explicitly
cover migrants, yet implementation of these approaches remains incomplete
129
and many migrant workers in such settings are unaware of the health benefits to which
they are ostensibly entitled.
130
The stigmatisation and scapegoating of immigrants, including the risk of death or
injury from increasingly coercive border control practices and acts of anti-immigrant
violence, contribute immeasurably to their susceptibility. Migration could lead to
discontinuity and fragmentation of health care, a particularly serious problem for
people with chronic diseases. Health risks are compounded when migration is the forced
result of military conflict or humanitarian emergency, which can create especially
chaotic conditions and prove particularly disruptive to service systems. In 2018,
results of a phylogenetic analysis in Ukraine suggested that migration resulting from
civil conflict in eastern Ukraine led to a rapid redistribution of HIV infection westward
and an apparent increase in HIV drug resistance.
131
In an increasingly mobile world, steps to address the health needs of people on the
move are crucial to the future of global health. In the push to achieve universal
health coverage, countries need to take on board lessons learned from Thailand's pioneering
provision of comprehensive health coverage for migrants living within its borders.
132
In regions with extensive cross-border migration, innovative regional efforts will
be needed to ensure continuity of care. Migrants should have access to health navigators
and other health services in their own language. In close collaboration with other
civil society partners, health advocates should energetically oppose demagogic efforts
to stigmatise migrant communities.
Related health issues
To date, the greatest focus on linking HIV with the broader global health field has
occurred with respect to specific health problems that overlap with HIV. These include
diseases that share modes of transmission as well as comorbidities that often accompany
HIV infection.
HIV, NCDs, and the future of global health
The future of the HIV response is intrinsically linked with the future of global efforts
to address NCDs. Due to the effectiveness of ART, the HIV population is steadily ageing
over time, with the number of people older than 50 years who are living with HIV increasing
by 36% between 2012 and 2016.
1
In 2016, sub-Saharan Africa was home to 3·7 million people (65 %) of the world's people
living with HIV who are older than 50 years.
1
As people live longer with HIV and depend on ART for decades, the care of people living
with HIV will increasingly focus on prevention and management of NCDs. People living
with HIV have an increased risk of many age-associated diseases,
133
including cardiovascular diseases,
134
neurocognitive disorders,
135
end-stage renal disease, and non-AIDS-defining cancers.
136
NCD risks appear to be less pronounced for people who initiate HIV treatment at higher
CD4 counts and, presumably, for those using modern ART regimens with fewer known negative
side-effects.
137
As diverse stakeholders coalesce to create a global movement to address NCDs, experiences
in the HIV response (including its advocacy successes, community engagement, models
of care, and innovation to ensure access to essential diagnostics and medicines) potentially
hold important lessons for the NCD community.
138
Already, the global attention to NCDs has surged, as reflected in the creation of
the NCD Alliance and the Lancet NCD Action Group, the upcoming Third High Level Meeting
on NCDs at the UN's General Assembly in 2018, the WHO-commissioned Independent High
Commission on NCDs, and grassroots movements to increase cancer awareness and funding
for cancer research. However, much greater political commitment, and the willingness
to stand up to entrenched financial interests such as the tobacco and food industries,
139
will be needed if NCDs are to receive the attention they warrant.
140
The NCD agenda has a clear potential to catalyse action to address the structural
determinants of health. Structural approaches (ensuring smoke-free environments, banning
or restricting advertising for tobacco or alcohol products, using taxes to discourage
use of tobacco or alcohol, reducing salt and sugar content in packaged foods and beverages,
and replacing trans-fats with healthier alternatives) are pivotal to efforts to reduce
NCDs.
141
Given the powerful degree to which socioeconomic status influences susceptibility
to NCDs,
142
strategies to alleviate poverty also support prevention of NCDs. As structural action
to address NCDs requires action in multiple domains (eg, social protection, trade,
agriculture, taxation and finance, agriculture, manufacturing, labour), it is important
that health routinely be taken into account in policy development processes. Toward
the goals of more integrated and universally accessible health systems and sustainable
health for all, policy development should prioritise structural approaches that generate
health benefits for diverse populations and health conditions. As prevention of NCDs
involve substantial shifts in social norms and practices (eg, smoking and alcohol
consumption, diet, indoor cooking practices), engagement of communities is essential.
For some NCDs, prevention technologies must be brought to scale, actively promoted,
and made broadly accessible. These include nicotine replacement and other smoking
cessation tools, as well as vaccines for the hepatitis B virus and human papilloma
virus. Cognitive behavioural interventions, akin to the behaviour change theories
and approaches that have been associated with reduced HIV risk behaviours and new
HIV infections,
7
have a role in reducing the modifiable risk behaviours that might increase NCD risks.
Experience in the HIV epidemic has taught that efforts to prevent a disease are often
less effective if treatment for the disease is unavailable. Until recently, the global
health discourse on NCDs focused almost exclusively on prevention, implicitly assuming
that treatments would remain out of reach for the foreseeable future. The growing
global movement on NCDs, as in the HIV response that preceded it, is rightly insisting
on urgent action to make NTD treatments affordable and widely available.
143
Although the HIV response is justifiably proud of having created service systems capable
of delivering ART to millions of people, the health-systems challenges associated
with NCDs are even greater than they were for HIV. Effectively addressing NCDs will
require reconfiguration of health programmes and individual clinics and will demand
new investments in health workforce training and development
144
to increase expertise in management of cardiovascular disease, oncology, geriatric
medicine, radiotherapy, and other NCD-related disciplines. Comprehensive and integrated
care needs to be established as the working norm for health systems, with primary
care as the cornerstone. Models of community-based and community-delivered care, which
prioritise self-care and differentiated services for people living with HIV, have
potentially broad applicability to the management of NCDs.
145
Capacitating health systems to address multiple health problems in an integrated manner,
including through co-located services, will improve efficiencies and aid in destigmatising
both HIV and NCDs.
In joining hands with the NCD field, the HIV community will also need to evolve. Moving
forward, the HIV response must transcend its singular, if imperative, focus on viral
suppression and recognise that prevention and control of NCDs are equally pivotal
measures of success. Vertical health programmes have driven much of the expansion
of health capacity in LMICs in recent years; they have also created professional silos
that are often jealously guarded. Strong action will be needed to overcome these tendencies
and persuade diverse health-care cadres and constituencies to understand the transformative
potential of more integrated and comprehensive approaches that preserve or improve
quality. For both national governments and international health donors, new funding
formulae might be necessary to incentivise integrated and multidisease service models.
Multidisease health screening models have already proven effective in addressing not
only HIV but also hypertension, diabetes, and childhood illnesses.
146
To expand the evidence base on the benefits and costs of integrating HIV and NCD programmes,
the Commission conducted modelling exercises to examine the health and financial effect
of multidisease screening programmes for HIV and NCDs in South Africa and Kenya.
Integration of sexual and reproductive health services
The rationale for integrating HIV and sexual and reproductive health and rights (SRHR)
services is compelling,
147
as individuals seeking or needing SRHR and HIV services are likely to face interrelated
risks (eg, of sexually transmitted infections and HIV infection, unintended pregnancy,
high-risk pregnancy, perinatal transmission of HIV, gender-based violence) and have
interrelated needs (for sexually transmitted infections and HIV detection and treatment,
contraception, antenatal or postnatal care, prevention of mother-to-child transmission,
pregnancy termination, and sexuality education and counselling). For such patients,
the ability to receive integrated care (in a single setting, and in a single day)
offers substantial benefits in terms of convenience and cost. In practice, however,
for a range of political, strategic, and funding reasons, efforts to integrate HIV
with other SRHR services have been minimal for much of the pandemic's history.
Funding and structures created to respond to the global AIDS crisis, while critical
to saving lives, contributed to the separation of HIV and SRHR: the establishment
of UNAIDS in 1996, which anchored HIV firmly outside of the SRHR framework; the MDGs
in 2000, which ignored SRHR altogether and defined a separate goal for HIV/AIDS; and
the Global Fund, which has been a lifeline to millions of people around the world,
but, at the time of its creation in 2002 and until relatively recently,
148
focused little attention or funding on SRHR, except with respect to services to prevent
vertical transmission of HIV.
149
The separation of HIV from SRHR in these structures and funding mechanisms contributed
to an over-medicalisation of the HIV response and shifted attention away from addressing
the epidemic in the context of sex and sexuality. Consequently, other elements of
SRHR (eg, abortion, contraception, and comprehensive sexuality education for youth)
became easy targets for political agendas already seeking to eliminate access to such
services. Moreover, this separation has undermined efforts to firmly establish HIV
and SRH service delivery in a human rights framework, prioritising bodily autonomy,
sexual rights, and access to information and services,
150
which has been a contributing factor to violations of sexual and reproductive rights
of women living with HIV, such as the use of forced or coerced sterilisation or abortion.
151
Although notable, if uneven, progress has been made in integrating services for the
prevention of mother-to-child HIV transmission in broader SRHR approaches,
152
progress in addressing the SRHR needs of women, girls, and sexual minorities remains
wholly inadequate. Even in high-burden settings in sub-Saharan Africa, where a substantial
number of women need services to prevent both unintended pregnancy and HIV, integrated
services are rare.
153
Marginalised populations at increased risk of HIV infection (including sexual minorities)
have additional SRHR needs that are often unaddressed by SRHR services that primarily
cater to married or coupled women of reproductive age.
153
Integrated definition of sexual and reproductive health and rights
The Guttmacher-Lancet Commission on Sexual and Reproductive Health and Rights
154
defines sexual and reproductive health as “a state of physical, emotional, mental,
and social well-being in relation to all aspects of sexuality and reproduction, not
merely the absence of disease, dysfunction, or infirmity. As such, a positive approach
to sexuality and reproduction should recognise the role played by pleasurable sexual
relationships, trust, and communication between partners in promoting self-esteem
and overall well-being”. The Commission defined an essential package of sexual and
reproductive health interventions and emphasised that the achievement of sexual and
reproductive health depends on realisation of sexual and reproductive rights, which
are based on the human rights of all individuals to: have their bodily integrity,
privacy, and personal autonomy respected; freely define their own sexuality, including
sexual orientation and gender identity and expression; decide whether and when to
be sexually active and choose their sexual partner (or partners); decide whether,
when, and by what means to have a child or children, and how many children to have;
and have access over their lifetimes to the information, resources, services, and
support necessary to achieve all the above, free from discrimination, coercion and
violence.
Effective integration of HIV and SRHR services requires action in diverse health service
domains, including contraception, maternal and newborn care, and abortion services.
In 2017, 43% of the 206 million pregnancies in LMICs were unintended, and 84% of these
unintended pregnancies were in women who had an unmet need for modern contraception.
98
In 2017, 37% of women who gave birth in developing countries did not receive the recommended
minimum of four antenatal care visits, 28% gave birth outside a health facility, and
308 000 women in developing countries died from pregnancy-related causes.
98
HIV–SRHR service integration can occur either by introducing HIV prevention and testing
into the current suite of contraceptive, maternal and child care, and abortion services
or by improving access to these types of SRHR services for people living with HIV.
When HIV and SRHR services are functionally integrated, important improvements can
be achieved in HIV testing rates, condom use, and selected indicators of quality of
care.
153
We modelled these interactions for the potential benefit of integrated services in
Nigeria (figure 10
).
Figure 10
Prevention of mother-to-child transmission of HIV in Nigeria
Mothers and children in Alausa Area of Lagos, Nigeria, during a state-sponsored educational
programme on prevention of mother-to-child transmission of HIV. Credit: © 2014 Kunle
Ajayi, Photoshare.
The important intersections between use of specific hormonal contraceptive methods
and various HIV-related risks further buttress the rationale for integration of contraceptive
and HIV services. Observational data suggest a potential association between use of
the progestin-only injectable contraceptive depot medroxyprogesterone acetate (DMPA)
and risk of HIV acquisition in women exposed to the virus.
155
In updated guidelines, WHO in February, 2017, recommended that women considering use
of progestin-only injectables be advised about these concerns, the uncertainty over
whether the association is causal, and how to minimise their risk of acquiring HIV.
156
Services for the prevention, diagnosis, and treatment of sexually transmitted infections
offer an important platform for integrating HIV in broader SRHR services. Fully capturing
the potential synergies and complementarities between sexually transmitted infections
and HIV prevention will necessitate a more holistic and context-specific approach
to sexual health. As an example of HIV–STI integration, the Dean Street Express clinic
in London, UK, provides a comfortable drop-in facility where individuals input sexual
risk information in kiosks, privately self-collect their oral, rectal, and genital
specimens for detection of sexually transmitted infection, have specimens delivered
via pneumatic tube to an onsite laboratory, and receive their results via text messaging
within several hours. Another approach to enhance sexual health is the New York City
PlaySure sexual health programme, which educates at-risk persons that HIV medications
used for treatment, PrEP, or post-exposure prophylaxis (PEP) can protect the health
of individuals irrespective of serostatus. Paired with an integrated package of sexual
health services that include routine sexual health screenings and rapid initiation
of antiretroviral medications for either prevention or treatment, New York's Status
Neutral model uses sexual health services as a gateway to transition from safety net
services to more longitudinal and comprehensive care.
Scaling up an integrated and synergistic approach to sexual health confronts important
obstacles that will need to be overcome. Notably, many primary care providers do not
routinely ask important questions about sexual health. Because medical and professional
schools often omit sexual history taking in medical training, health workers often
miss important opportunities for prevention and fail to provide their patients with
good-quality services.
Transcending the historic separation between HIV and sexual health will rely on bold
leadership, innovative approaches, new funding models, and new partnerships that help
dissolve the siloes in which these related efforts have operated. Integrating HIV
and SRHR will help ground these linked enterprises in a human rights framework that
prioritises bodily autonomy, sexual rights, and access to information and services.
Global health emergencies: Ebola, Zika, pandemic flu, and antimicrobial resistance
Global health emergencies related to infectious diseases in recent years have highlighted
the pressing need for all countries to be prepared for the advent of health emergencies
and have the capacity to respond rapidly and effectively. In recent years, the Ebola,
Zika, and pandemic influenza viruses moved through specific regions quickly, with
devastating effects on people's lives, communities, and economies. With increasing
population pressure, urbanisation, travel and displacement, climate change, habitat
destruction, and global antimicrobial use, the world will inevitably see more frequent
health emergencies related to infectious diseases.
157
Some of these emergencies are highly likely, such as pandemic influenza, which will
always reappear.
158
Others emergencies such as Middle East respiratory syndrome or severe acute respiratory
syndrome might be entirely new infections that will require rapid collection of data
to understand the natural history. New presentations could be of known infections
but in non-immune communities, as recently seen with the Zika virus outbreak, or the
emergence of drug-resistant strains of known pathogens, including Mycobacterium tuberculosis
and HIV.
159
Many disease-control interventions are relevant irrespective of the particular health
challenge, including community-based care delivery, the requirement for and training
of a diverse health workforce able to handle infectious diseases, control of nosocomial
spread, research methodology, and infrastructure for effective community engagement
(figure 11
). All infectious disease emergencies require strong laboratory and surveillance systems
to detect and understand the rapidly changing epidemiology and drive an evidence-informed
and country-specific response. The HIV response has been an example of community engagement
and empowerment that has led to accelerated research and more effective programme
implementation in many parts of the world. The strengths of the HIV response can therefore
inform responses to global health emergencies.
Figure 11
Monitoring babies for signs of congenital Zika syndrome in Honduras
At Tela Hospital in El Progreso City, Honduras, Ileana Mayes Flores, the only geneticist
in the public sector of Honduras, examines Aylin Meja, a baby aged 3 months whose
mother, Sandra Meja aged 19 years, was infected with the Zika virus during pregnancy.
The medical staff is closely monitoring her baby for signs of congenital Zika syndrome.
Credit: © 2017 Brendan Bannon/USAID, Photoshare.
Although modes of transmission might vary in each health emergency, comparable groups
are often at risk of multiple diseases, and similar interventions are available to
block transmission. For example, both Zika and Ebola virus infections were sexually
transmissible and transmissible from mother to child. As in the case of HIV, fears
and suspicion of people infected with Ebola virus, and to a lesser extent Zika virus,
have prompted calls for quarantine, with associated paranoia and misinformation.
160
Often, infections and their associated stigma disproportionately affect the reproductive
rights of women. Dispelling stigma and ensuring a non-discriminatory and evidence-informed
response is important to balance the rights of individuals with appropriate disease
control measures.
Although there is much common ground, health emergencies differ in important respects
from HIV. First, whereas the HIV epidemic is a long-wave event that has unfolded over
many years, health emergencies in infectious diseases are often acute, leading to
major short-term disruption. Second, a very rapid political response is needed, often
with mobilisation of vast amounts of money, which might shift resources away from
HIV programmes. Third, there is a limited research base, and few or no known interventions
at the time an emergency response is needed.
In the absence of an activist community, inappropriate decisions in health emergencies
can be made for and not with affected communities. In the HIV response, these communities
have been built, strengthened, and sustained over decades, not days or weeks. The
affected community might not always be easily defined, as, for example, seen in pandemic
influenza epidemic or in the case of co-infection and overlaps in disease susceptibility.
Infectious disease emergencies can profoundly disrupt health services and supply chains,
leading to cascading health-system failures that affect people with a wide range of
diseases.
161
Integration of HIV and global health responses could be assisted by a high-level political
platform bringing people and organisations together to transcend administrative and
academic silos and to build broadly responsive and effective health systems. Identifying
key stakeholders in emergency response preparedness and resource mapping of relevant
capabilities in laboratory diagnostics, surveillance and epidemiology, clinical care,
clinical trials capabilities, ethics, and target communities will facilitate integration.
Investment in communication across sectors could enable the development of a business
model for rapid mobilisation of resources and effective responses to global health
emergencies.
Tuberculosis
The basic approach to controlling the linked epidemics of HIV and tuberculosis is
deceptively straightforward. People with HIV–tuberculosis co-infection who develop
active tuberculosis disease need to be found and treated promptly with tuberculosis
drugs and ART. Co-infected individuals at risk of developing tuberculosis must be
treated with ART and with isoniazid preventive therapy (IPT).
In reality, however, controlling tuberculosis in the context of HIV has proven to
be a major global health challenge. Globally, less than half of tuberculosis cases
are diagnosed before death, and only about half of all patients with tuberculosis
know their HIV status.
162
Less than half of all people living with HIV who have tuberculosis are estimated to
be receiving ART, but HIV treatment coverage is 77% among notified tuberculosis cases.
162
In 2016, 60% of countries with high HIV–tuberculosis burden did not report the provision
of IPT.
162
Despite these challenges, the improvements in HIV care and treatment, recognition
that both diseases coexist, and a move to more active case finding led to a reduction
in annual mortality from tuberculosis in people living with HIV by 33% between 2005
and 2015.
1
The global failures to address tuberculosis in the context of the HIV epidemic demonstrate
the challenges of service integration, even when the biology of pathogens and the
clinical realities of disease interactions clearly argue for integration. Tuberculosis
and HIV programme siloes are object lessons in the difficulties of providing better
and more streamlined care for patients in dual epidemics. Inadequate HIV–tuberculosis
integration results in suboptimal service coverage, limited access, missed opportunities
for prevention, diagnostic and therapeutic intervention, and inefficient use of resources.
Although undoubtedly beneficial, integration of HIV and tuberculosis services is not
always easy to achieve. Infection control, particularly in health-care settings, is
necessary but often difficult under existing conditions, with multidrug-resistance
tuberculosis and extreme multidrug-resistance tuberculosis posing lethal risks for
people living with HIV. Health workforce shortages undermine effective management
and control of HIV–tuberculosis co-infection, and health workers addressing HIV–tuberculosis
co-infection are also at substantial risk of occupational exposure to tuberculosis.
As HIV and tuberculosis programmes were developed separately, with different funding
streams and constituencies, ensuring ongoing communication and collaboration between
these programmes might be hindered by resistance from turf-conscious programme implementers
and planners. Tuberculosis and HIV–tuberculosis co-infection are particularly challenging
issues for incarcerated persons worldwide.
163
According to a review of HIV, viral hepatitis, and tuberculosis burden in prisoners
and detainees, the most effective way to reduce these infections in prisoners and
in the broader communities from which they come is to reduce mass incarceration for
people who inject drugs.
163
Numerous efforts worldwide, often extremely successful, have been made to improve
HIV–tuberculosis collaboration and linkages. In Khayelitsha, South Africa, HIV and
tuberculosis programmes were physically merged in 2003 to enable so-called one-stop
shopping for people with HIV–tuberculosis co-infection.
164
In Tanzania, PASADA, a faith-based organisation providing comprehensive HIV care,
collaborated with national tuberculosis authorities to integrate tuberculosis services
and improve laboratory capacity, harmonise staff training and reporting, dedicate
a room within the clinic for patients with tuberculosis, and link services with a
strong social support system. In India, collaboration at the national level has driven
systematic implementation of collaborative HIV–tuberculosis activities across the
country.
Notwithstanding these promising examples, HIV and tuberculosis programmes continue
to operate independently in most parts of the world. Joint efforts are warranted for
coordination of national responses to HIV and tuberculosis, including strengthened
surveillance, programme planning, and monitoring and evaluation. Intensified tuberculosis
case finding, scaled-up IPT, and a strengthened emphasis on infection control are
needed to reduce the tuberculosis burden in people living with HIV. Further efforts
are needed to ensure routine HIV testing, access to HIV prevention methods, ART, and
HIV care and support for patients with tuberculosis. Collaborative programmes for
HIV and tuberculosis should build on well developed community systems and civil society
engagement and incorporate interventions for poverty alleviation and social protection
as well as specific measures to reduce the HIV and tuberculosis burden in prisoners
and migrants. Collaborative HIV–tuberculosis programmes must be prepared to manage
the most common co-occurring health conditions in individuals with HIV–tuberculosis
co-infection such as diabetes, alcohol and drug use disorders, health conditions related
to tobacco smoking, and lung diseases. These strengthened collaborative programmatic
efforts should be supported by robust investments in research and innovation that
will support the discovery, development, and rapid uptake of new tools and interventions
as well as the research to optimise implementation and catalyse further innovation.
Viral hepatitis
The links and synergies between HIV and viral hepatitis are evident, in part because
of overlapping routes of transmission, overlapping populations at highest risk of
acquisition and transmission, and common approaches to prevention and treatment. HCV
infection, however, by marked contrast with HIV, is now curable. With a relatively
short course and well tolerated oral therapy, a cure is reliably achieved in more
than 95% of infected persons.
165
Isolation of HCV and development of a curative regimen are recent developments, and
there is reason for hope that rapid gains can be made in diminishing the burden associated
with the infection. Hepatitis B virus was isolated much earlier than Hepatitis C virus,
and global coverage of the vaccine, which is cheap and effective, for newborn babies
reached 84% in 2016.
166
The HIV epidemic, including the desperation for effective therapies it elicited in
its early years and the changes it wrought to drug development, regulatory policies,
and the global infrastructure for clinical trial enrolment, laid the foundation for
the development of the highly effective, safe, all-oral, curative therapies that have
emerged for HCV infection. As in the case of HIV, originator companies have entered
voluntary license agreements with generic manufacturers to produce and distribute
direct-acting antivirals, which has substantially lowered treatment costs in the LMICs
covered by these agreements. Due to differences in epidemiological burden between
HIV and HCV, with substantial concentration of HCV infection in many upper-middle-income
countries and high-income countries that are excluded from voluntary licenses for
direct-acting antivirals, costs of these drugs remain prohibitive in many parts of
the world.
167
Community mobilisation has had an essential role for responses to both HIV and HCV.
Civil society mobilisation to expand treatment access for HCV infection is rapidly
increasing to demand development of national treatment guidelines, innovative use
of intellectual property law to lower the cost of direct-acting antivirals, and routine
availability of diagnostic and therapeutic tools.
Treatment as prevention, a concept made feasible by the advent of effective therapies
to achieve HIV control, has the potential to be realised for HCV infection through
expanded use of direct-acting antivirals, the first highly effective curative treatment
for a chronic viral disease. Elimination of HCV would inspire the global health field
and generate important lessons pertinent to efforts to control other infectious diseases
through the delivery of safe, effective, and short-term treatment to marginalised
populations.
To realise the elimination goal for viral hepatitis, a major shift will be required
in the management of these diseases. Here, too, lessons from the HIV response are
instructive, notably the evolution in HIV treatment from a focus on the sickest to
recognition of the benefits of treatment for all people living with HIV. Treatment
for HCV infection is often reserved for the sickest patients, and many people who
could benefit from treatment have been denied therapy because of risk behaviours (eg,
ongoing injection drug use). As the right to treatment has proved such a powerful
and animating force in the HIV response, a similar rights-based approach is needed
to ensure the access of all people with chronic HCV infection to treatment services.
In yet another echo of experience with HIV, the HCV treatment revolution has the potential
to draw marginalised people into health services that have historically been hostile
or unwelcoming. Health systems must adapt to provide the needed array of health and
social services for vulnerable populations. The HCV response, like the HIV response,
brings into sharp relief the importance of ensuring investment in research and development
of new medicines, maintaining sustainable health budgets, and leveraging social and
health policy to prevent the spread of infectious diseases.
Differentiated care for HIV
Models of service delivery developed for the rapid scale-up and maintenance of ART
are potentially useful for informing care strategies for other diseases, including
the growing burden of NCDs. Taking what began as a standardised and somewhat rigid
approach to the delivery of HIV treatment, people living with HIV and the communities
in which they live pioneered new approaches to service delivery.
Although these adaptations are diverse, they share the central idea of responding
to client and health systems needs. In rural Mozambique, groups of clients took turns
travelling to the health centre to collect refills of antiretroviral medicines to
avert the need for individual patients to travel long distances for monthly refills.
168
Networks of people living with HIV in Uganda opened community drug distribution points
closer to communities to enhance access.
169
In urban South Africa, adherence clubs offered peer-based adherence support and reduced
the frequency with which virally suppressed clients needed to attend clinic, helping
decongest overcrowded clinics.
145
Importantly, these service delivery innovations not only increase client convenience
and minimise health-system burdens, but they also generate excellent health outcomes,
as measured by retention in care and rates of viral suppression.
170
Together, these various service delivery adaptations have become known as differentiated
service delivery. Consistent with a people-centred approach to health care, differentiated
service delivery recognises and responds to the diversity of client needs.
171
In 2016, WHO formalised the paradigm shift in HIV service delivery, replacing the
standardised one-size-fits-all model, which had long been recommended for HIV services,
with distinct packages of care for different groups of people living with HIV.
172
Differentiated service delivery illustrates not only how service delivery innovations
can improve efficiency and effectiveness but also how communities can shape and inform
health systems.
Substance use disorders
Marginalised communities, including but not limited to sex workers and sexual minorities,
often experience addiction in the context of multiple health and social disadvantages
(eg, mental health disorders, abuse, police harassment, homophobia, and transphobia).173,
174 In particular, the criminalisation of substance use and of substance users has
long aided and abetted transmission of HIV and other diseases.
175
The regions where the HIV pandemic continues to expand (eastern Europe and central
Asia, the Middle East, and north Africa) share substantial HIV epidemics in people
who inject drugs and have harsh prohibitionist drug regimes.
175
In Russia, home to the largest epidemic in eastern Europe and central Asia, all opioid
substitution therapy is illegal and the country instead relies heavily on coercive
detention for rehabilitation (figure 12
).
76
In the USA, an expanding opioid epidemic has led to outbreaks of HIV and HCV, especially
in rural communities where a high proportion of new cases are young, white women.
176
Figure 12
Patients undergo drug detoxification while handcuffed to their beds at a programme
for heroin addiction in Ekaterinburg, Russia
Credit: Brendan Hoffman.
Untreated substance use disorders are associated with reduced retention in HIV care
and worsened HIV-related health outcomes.
177
Drug dependency requires intensive, personalised treatment such as MAT with methadone,
buprenorphine, and other opioid agonists. These services for drug addiction are fully
compatible with HIV prevention and treatment services, including HIV testing and provision
of ART, PrEP, syringes, condoms, and overdose prevention (eg, naloxone). A team in
northeast USA developed culturally tailored programmes that use innovative means to
provide MAT, work with correctional systems, and understand the interplay between
substance use, violence and victimisation, sex work, and behavioural health morbidities.
178
This approach was subsequently adapted to other settings, including Ukraine and Malaysia.
Globally, integration of HIV and addiction services is scarce, in part because of
stigma. People with substance use disorders are often excluded from MAT or other services
if they have a comorbid psychiatric disorder (and vice versa), an approach that not
only worsens health outcomes but also compounds the marginalisation experienced by
people with these disorders. In many settings, treatment for substance use and HIV
operate in silos, resulting in fragmented care and suboptimal clinical outcomes. Meaningful
integration of services for people with substance use and HIV requires a health workforce
that is culturally competent and professionally skilled to create clinical environments
that promote service access, engagement, retention, and medical adherence. Modelling
exercises on behalf of the Commission examined the epidemiological and cost effect
of such a one-stop shopping approach for people who inject drugs in Russia.
Mental health disorders
There are multiple reasons for the frequent co-occurrence of mental health disorders
and HIV, with many stemming from the internalised stigma and stress that are often
associated with behaviours that can result in HIV transmission (eg, sex between men,
gender variance, or injecting drug use).
179
Internalised stigma associated with HIV is common not only in marginalised populations
but also in settings with high-burden epidemics in heterosexual people, linked in
many cases to shunning or shaming by families, friends, and social arbiters, including
faith leaders. In one recent US cohort, more than one in five patients had clinically
significant depression, 22% of the cohort had an anxiety disorder, and a comparable
proportion of the cohort had a clinically significant substance use disorder.
180
The linkages and overlaps between HIV and mental health are multifaceted. Depression,
especially when it occurs alongside substance use and other health and social conditions,
can contribute to risky sexual behaviours.
181
Untreated depression is also correlated with reduced capacity for self-care and retention
in HIV care.
182
These associations are hardly unique to HIV as untreated depression and other psychiatric
disorders are strongly linked with non-adherence in patients with cardiovascular and
other NCDs.
183
One of the most striking features of the intersection between HIV and mental health
is the common co-occurrence of multiple coexisting psychosocial and clinical challenges
in people with or at risk of HIV.
184
The presence of these syndemic conditions potentiates sexual transmission risk
182
and non-adherence to antiretroviral medication regimens.
172
Because of the centrality of mental health to the management of a broad array of health
conditions, mental health services should be fully integrated into the health system
and ideally co-located with other related health services such as treatment and care
for HIV, NCDs, and substance use disorders.
185
However, as confirmed by findings from a situation analysis in five LMICs, most health
systems are not prepared to provide an integrated and scaled-up access to mental health
services.
186
Although mental health disorders are one of the leading causes of disability worldwide
52
and one in four people will need mental health services at some point in their lives,
many countries invest as little as 2% of total health spending on mental health services.
187
Immediate efforts are needed to implement the actions outlined in WHO's mental health
action plan 2013–20.
188
Implementation of these action steps will require major new investments in mental
health training for health personnel and a decentralisation of mental health services
to increase access to community-based services.
189
Health systems and structural change
Perhaps more than any health problem of our time, HIV has shown both the importance
of strong health systems and how social, legal, economic, and structural factors affect
susceptibility to disease and the capacity of societies to mount effective public
health responses. To date, however, the success of the HIV response in addressing
these social and structural factors has been imperfect at best, in part due to the
failure to translate key insights into meaningful policies and programmes. The Agenda
for Sustainable Development, which is premised on the indivisibility of the broader
development agenda, affords new opportunities to integrate attention to social and
structural issues as a fundamental pillar of global health. Indeed, although health-specific
targets are clustered under SDG 3, the future of global health is integrally linked
with the vision of SDG 16 to “promote peaceful and inclusive societies for sustainable
development, provide access to justice for all and build effective, accountable and
inclusive institutions at all levels”. Such important change will not be easily achieved,
but the long-terms benefits could be substantial.
Just as disease-specific and population-specific funding for health can create silos
that impede greater integration, having separate budgets for health and other social
sector programmes makes it difficult to address the social and structural issues that
increase susceptibility to disease and diminish use of health services. Health outcomes
are affected by outcomes from other sectors such as education,
190
housing,
191
human rights, gender and women's rights, and law enforcement. Other sectors also have
a crucial role in delivering services that address the needs of people affected by
HIV or other health problems; for example, social protection that provides cash transfers
or undertakes programmes to address the needs of susceptible households.
Overcoming these silos will need a clear and strong political mandate for diverse
sectors and ministries that maximise and fully leverage policy and programmatic synergies
as well as a strong commitment of each of these sectors to work together. Incorporating
multisectoral approaches in budgetary and strategic planning is a potentially valuable
avenue for addressing social and structural issues. Under this approach, key sectors
or ministries participate in formal health planning processes, receive clear budgetary
outlays associated with concrete deliverables, and participate in monitoring, evaluation,
and accountability systems to ensure that these social interventions achieve desired
health outcomes.
Building strong health systems
Across diverse populations and disease priorities, health system weaknesses impede
efforts to improve health and wellbeing and to advance towards the goal of universal
health coverage.
Well functioning health systems will be essential to sustaining ART in the decades
to come and to promoting holistic, client-centred, one-stop-shopping models that integrate
diverse services. New service delivery models that prioritise patient self-care and
decongest clinics will be needed, and innovative approaches will be necessary to maximise
outcomes from available health personnel.
Urgent and sustained efforts are needed to build and preserve human resources for
health. In addition to essential new investments in traditional medical education,
the shifting or sharing of clinical tasks from higher-cadre to lower-cost health workers
will be needed to improve health-service efficiency and expand the reach of health
services, especially for remote and marginalised communities. Increased use of trained
community health workers offers an important task-shifting strategy for rationalising
health spending and bringing services closer to the communities that need them. Compensation
and training costs for community health workers are much less than for higher-cadre
health workers, and the availability of community health workers enables doctors and
nurses to focus more time on the skills for which they are specially trained.
192
Numerous models for community health workers are already in operation in diverse regions,
including in high-income countries. Ideally, community health workers are drawn from
the communities they serve, receive extensive training that enables them to diagnose
and address multiple health conditions, and are compensated, supervised, and fully
integrated into health systems. Integrating community health workers into health systems
has been shown to increase immunisation rates, enhance access to diverse health services,
and reduce childhood mortality.193, 194, 195
The financing of health care can have a major effect on the efficiency of health services.
To improve efficiency and quality of care, policy makers are advised to optimise the
mix of payment strategies (eg, capitation, case-based reimbursement, fee-for-service,
per diem) that incentivises service access, quality of care, satisfaction of provider
and client, and other system priorities.
196
Evidence suggests that carefully designed financial incentives to patients could increase
use of preventive care, which improves health outcomes and potentially averts more
costly therapeutic interventions in the future.
The HIV response has undoubtedly generated benefits for health systems. An independent
evaluation of PEPFAR found that the bilateral programme had increased national capacity
for commodity forecasting, procurement, storage, distribution, and tracking.
197
Beginning in 2013, the Global Fund began soliciting proposals not only for specific
disease programmes but also for health-systems strengthening. Global Fund grants have
underwritten a variety of activities to buttress procurement and supply management,
including expanded warehousing capacity in Tanzania, digitising and streamlining supply
logistics in Laos, and revising and updating of the essential medicines list in Cambodia
(Shakarishvili G, Global Fund to Fight AIDS, Tuberculosis and Malaria, personal communication).
Despite these strategic investments, stock-outs of antiretroviral medicines remain
a persistent problem in sub-Saharan Africa,
198
especially with respect to new regimens.
199
Weaknesses in procurement and supply management are not confined to Africa or to HIV
medicines but instead represent a systemic challenge that demands high-level and sustained
attention. For example, in the Mekong region, where a rapid surge in malaria resistance
has caused global alarm, fake or substandard anti-malaria medicines are common.
200
Maintaining separate disease-specific systems for procurement and supply chain management
wastes money, reduces incentives for service integration within health systems and
facilities, and siphons scarce funding away from needed systemic investments.
Comparable actions are needed to strengthen and sustain laboratory systems. Independent
evaluators found that PEPFAR's impact on national laboratory capacity has been “fundamental
and substantial”.
197
Investments by PEPFAR, the Global Fund, and other donors have resulted in the training
of tens of thousands of laboratory professionals, the purchase of new laboratory equipment,
and upgrading the degree of management and organisation in laboratory medicine, especially
in sub-Saharan Africa.
Although HIV has served as a shot in the arm for many laboratory systems, these functions
remain badly under-resourced. Maintenance of vertical funding streams for laboratory
medicine undermines efforts to apply laboratory technology and skills across diseases.
For example, although management of HIV and tuberculosis is critically linked, laboratory
services for the diseases often remain distinct and unintegrated. This represents
an important missed opportunity because certain laboratory tools, such as the nucleic
acid diagnostic networks created to support early infant HIV diagnosis, have the potential
to enable diagnosis of a range of diseases (Peter T, Clinton Health Access Initiative,
personal communication).
Structural change and health in lesbian, gay, bisexual, transgender, and intersex
(LGBTI) communities
In a singular achievement, the global HIV response has yielded new opportunities for
gay and bisexual men and others in LGBTI communities to be recognised as citizens,
rights holders, and beneficiaries of public health programmes in their own countries.
Donor funding has played a pivotal part in supporting LGBTI communities to engage
in HIV leadership and in developing programming in gay and bisexual men and other
marginalised populations. Among 93 countries reporting the existence of HIV services
for gay and bisexual in 2005–13, 67 countries said these programmes were wholly dependent
on international funding.
Bringing an end to HIV exceptionalism risks rolling back this historic progress in
recognising and responding to the health and related needs of LGBTI people. For example,
replacing disease-specific and population-specific funding streams with general health-system
funding could jeopardise the sustainability of community-led organisations in the
many countries whose governments have proven either indifferent or openly hostile
to gay and bisexual men. Innovative models of service delivery, which communities
of gay and bisexual men have developed in the face of stigma and discrimination, could
well be lost.
Universal health coverage offers new opportunities to right many of these wrongs associated
with the longstanding underprioritisation of the health needs of LGBTI people. However,
while coverage is expanded to all, irrespective of demographic status, health systems
also must be transformed to respond to the diversity of the people they serve. This
will require the routine collection and analysis of disaggregated data to understand
health status in LGBTI sub-populations, to measure programme performance, and to assess
LGBTI communities' satisfaction with services.
Opportunities for integration: key conclusions of the Commission
In disease-specific and population-specific reviews, the Commission has identified
numerous opportunities (both in the immediate term and longer term) for synergising
HIV with the broader global health agenda and for advancing intersectoral action towards
universal health access (table
; panel 2
).
201
Table
Immediate opportunities for synergies through co-located services, by service platform
Population (or populations)
Co-located HIV and SRHR services
Women, adolescent girls, sexual minorities
Co-located HIV and antenatal services
Pregnant women
Co-located HIV and paediatric health services
Children living with HIV
Co-located and jointly planned HIV and tuberculosis screening and treatment services
People with or at risk of HIV–tuberculosis co-infection
Co-located HIV and HCV screening and treatment services
People with or at risk of HIV–HCV co-infection
Co-located drug treatment or rehabilitation for HIV, NSP, and MAT
People who inject drugs
Screening for HIV and NCDs
General population in high-burden settings
Management of NCDs in HIV service platforms
People living with HIV and people with or at high risk of NCDs
SRHR=sexual and reproductive health and rights. HCV=hepatitis C virus. NSP=provision
of clean needles and syringes. MAT=medication-assisted therapy. NCDs=non-communicable
diseases.
Panel 2
Longer-term opportunities to maximise synergies
Integrated care in mainstream health services
Key action items:
•
Health systems strengthening interventions (eg, payment systems, patient incentives,
procurement and supply management, workforce training, laboratory strengthening)
•
Progressive integration of treatment services for HIV and non-communicable diseases
•
Steps to ensure that all health services are adolescent-friendly
•
Clinic and community interventions to increase men's use of health-care facilities
•
Capacitation of health systems to address the needs of marginalised populations, including
sexual minorities and migrants
•
Steady progress towards universal health coverage (with HIV progressively folded into
broader health insurance schemes)
Addressing social and structural issues
Key action items:
•
Repeal of criminalisation laws
•
Multisectoral budgeting, planning, and accountability for results
•
Following through on women's equality and LGBTI agenda
•
Steps to ensure an enabling environment
LGBTI=lesbian, gay, bisexual, transgender, and intersex.
Integration of HIV and other health services: modelled scenarios
As indicated by the multiple domains in which integration of HIV and broader health,
social, and structural approaches is warranted, the opportunities for integration
are myriad. Actions to integrate HIV and global health aim to achieve win-win results,
whereby both HIV-related and non-HIV-related health outcomes are enhanced in a manner
that is cost-effective. Movements to integrate HIV into health systems will and should
be incremental at the outset, with integrated approaches tailored to national conditions.
Rather than attempt a rapid and wholesale transfer of vertical programmes to national
health systems, initial efforts might focus on more fully integrating HIV with services
to address other health issues (eg, sexual health, NCDs, tuberculosis). Especially
for marginalised populations that are not well served by mainstream health services,
early steps towards integration might focus on integrating HIV services with services
that specifically serve these populations (such as harm reduction services in the
case of people who use drugs).
Successful integration of HIV services with other health services requires an in-depth
understanding of setting-specific factors that drive the potential effect of new programmes
at a national level. Given the diversity of HIV epidemics and health systems, we studied
the potential effect of HIV integration in five countries with different HIV epidemic
profiles and health-system characteristics—thus requiring different approaches to
integration of HIV with other health services (figure 13
). In each country scenario, we estimated the population-level effect of integration,
not only in terms of HIV-specific outcomes but also in terms of potential effect on
other health conditions. In select countries, we additionally estimated the cost-effectiveness
of these programmes.
Figure 13
A multicountry modelling exercise to study the effect of HIV integration in various
settings
NCDs=non-communicable diseases. MSM=men who have sex with men. FSW=female sex workers.
ART=antiretroviral therapy.
South Africa: mobile multidisease screening for HIV and NCDs
The world's largest HIV epidemic is in South Africa, an upper-middle-income country,
where an estimated 7·1 million people have HIV, and the prevalence of HIV infection
is 18·9%.
1
South Africa also has a burgeoning epidemic of NCDs. 30% of women aged 55–64 years
have diabetes,
202
and the diabetes-specific mortality has been steadily increasing since 1997,
203
reaching 3·6% of all deaths in 2012.
204
Cardiovascular disease accounted for 18·5% of all deaths in South Africa in 2012,
204
and an estimated 31·8% of South African adults have hypertension, the leading risk
factor for cardiovascular disease.
205
Altogether, HIV, diabetes, and cardiovascular disease accounted for 51% of all deaths
in South Africa in 2012.
204
Although high levels of HIV diagnosis have been achieved in South Africa,
206
only half of diabetes and hypertension cases have been diagnosed, and disease is seldom
effectively controlled (figure 14
). Platforms that integrate screening for these three diseases have the potential
to address the urgent need for improved diagnosis of diabetes and hypertension.
Figure 14
South African health statistics and the potential effects of multidisease screening
(A) HIV estimates are obtained from the Thembisa model estimates for 2016, whereas
diabetes and hypertension estimates are from the 2012 South African National Health
and Nutrition Examination Survey. Controlled on treatment is defined in the case of
HIV as having a viral load less than 400 copies per mL, and in the case of diabetes
as a HbA1c concentration less than 7%. Estimates of treatment coverage and control
rates among hypertension cases are obtained from a national survey in 2010. (B) The
expected fraction of screened individuals testing positive, the expected fraction
of newly diagnosed individuals, and the expected fraction of individuals linking to
treatment services in the context of a multidisease screening programme implemented
between 2018 and 2028.
Several mobile multidisease screening interventions have been piloted in South Africa
207
(figure 15
) and other African countries.208, 209 To assess the potential effect and cost of
introducing a mobile screening service for diabetes, hypertension, and HIV in South
Africa, we extended an HIV model that was previously developed for South Africa, to
incorporate diabetes and hypertension screening (panel 3
). The model estimates that if such a multidisease screening programme were introduced
in 2018–28, and reached 10% of South African adults each year, the programme would
diagnose 492 000 new HIV cases, 1·21 million new diabetes cases, and 6·35 million
new hypertension cases. Expressed as a fraction of individuals screened, the proportion
newly diagnosed is expected to be lowest in the case of HIV and highest in the case
of hypertension (figure 14). The total number of new treated HIV, diabetes, and hypertension
cases would be expected to increase by 197 000, 543 000, and 2·1 million, respectively.
As a result of the increase in HIV diagnosis and treatment rates, the incidence of
adult HIV infection is expected to decrease by 3·5% in 2018–28, which is equivalent
to 69 000 infections averted.
Figure 15
Differented care in South Africa—The Tutu Tester mobile screening programme for HIV,
tuberculosis, diabetes, hyptertension, and body-mass index
Credit: Desmond Tutu HIV Research Foundation/Alexis Dominguez.
Panel 3
Modelling HIV, diabetes, and hypertension screening in South Africa
Thembisa is an integrated demographic and HIV model developed for South Africa. The
process of calibrating the model to data on HIV prevalence, HIV diagnosis, and mortality
has previously been described.206, 210 In this analysis, the prevalence of diabetes
(defined as a concentration of HbA1c ≥6·5%) and hypertension (defined as systolic
blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or current use of blood
pressure medication) was estimated from the age-specific and sex-specific prevalences
measured in the 2012 South African National Health and Nutrition Examination Survey
(SANHANES).
205
Age-specific and sex-specific rates of diagnosis for diabetes and hypertension were
estimated from the same source. The average annual proportion of the adult population
(aged 15 years and older) screened was assumed to be to 10%.208, 209, 211, 212 This
average proportion was scaled by age-specific and sex-specific adjustment factors
based on similar screening programmes in Uganda.
209
Uptake of screening was assumed to be independent of disease status and further assumed
to be constant over the period from July 1, 2018, to June 30, 2028. The proportion
of newly-diagnosed individuals who linked to care and started treatment soon after
diagnosis was set to 40% in the case of HIV,
213
45% in the case of diabetes, and 33% in the case of hypertension.
210
A more detailed description of the model is provided in the appendix, as are sensitivity
analyses with lower programme coverage and lower sensitivity and specificity of screening
for hypertension and diabetes.
Kenya: screening for HIV with hypertension and diabetes
Kenya has the joint fourth largest HIV epidemic in the world, with 1·6 million people
living with HIV in 2016.
1
Although the prevalence of HIV in adults (5·4%) is lower than in South Africa (18·9%),
1
the proportion of HIV that remains undiagnosed (30%)
214
is higher in Kenya than in South Africa (13%). As is the case across sub-Saharan Africa,
Kenya is experiencing an increasing burden of NCDs, which account for 27% of all deaths
and 50% of hospital admissions.
215
Much of this increase can be attributed to lack of screening and early detection of
NCDs, which in turn leads to late diagnosis and poor treatment outcomes. For example,
56% of people in Kenya have never had their blood pressure measured, and only 22%
of individuals with increased blood pressure or hypertension diagnosis report taking
treatment.
215
These enormous gaps in screening and treatment of NCDs are occurring in the context
of an overwhelmed health system and an HIV epidemic that has yet to be brought under
control.
A modelling scenario for integrated screening for HIV, hypertension, and diabetes
in Kenya is shown in panel 4
. At baseline and in the absence of additional intervention, the incidence of HIV
infection in Kenya is estimated to decrease by 13% in the next decade. The integration
scenario models a gradual increase in HIV screening and coverage of ART over time,
reaching a population-level coverage of 78% in 2028. This corresponds to an additional
4 117 912 person-years on ART in the next decade. With this intervention, the number
of new HIV infections is projected to decrease by 44% by 2028, corresponding to 216 655
new infections and 244 374 AIDS deaths averted (figure 16
). Sensitivity analyses of ART uptake suggested that even with only 40% treatment
initiation, the integration scenario would reduce the incidence of HIV infection by
23%. Given the longer life expectancy of HIV-positive individuals receiving ART, the
intervention results in only marginal improvements in HIV prevalence (1·4% reduction
by 2028), despite the substantial reductions in new infections.
Panel 4
Modelling scenario for integrated screening for HIV, hypertension, and diabetes in
Kenya
The Spectrum package was used to explore the potential effect of a country-wide campaign
to integrate screening for HIV, diabetes, and hypertension.
Baseline ART coverage in 2016 was maintained at a fixed level from 2018 to 2028.
Following the framework of project SEARCH,
146
we modelled a joint community-outreach campaign for HIV and NCDs screening in the
next decade (2018–28). We assumed that each year, a geographically distinct area of
Kenya comprising 10% of the population would receive the programme, and that 90% of
eligible adults aged 15 years or older would be successfully screened for HIV, diabetes,
and hypertension.
To model the potential effect on HIV-related outcomes, we ambitiously assumed that
this intervention could successfully initiate and retain 81% of newly diagnosed individuals
on ART (ie, assuming a target level of 90% linkage and 90% engagement in HIV care
after diagnosis). This corresponds to a 73% reduction in unmet need for ART in people
living with HIV in the next decade, modelled as a linear increase in the ART coverage
in each subgroup from 2018 to 2028.
Using a representative national survey,
215
we estimated the proportion of adults with, aware of, and receiving medication for
hypertension and diabetes. Based on the number of adults screened and the expected
uptake of treatment, we estimated the effect of the integrated intervention on awareness
of and treatment for hypertension and diabetes.
To assess cost-effectiveness, intervention costs were based on those reported in the
SEARCH study,
216
and the number of people receiving ART and HIV-related DALYs were obtained from Spectrum.
As most treatment costs and DALYs are incurred later in life for NCDs, we report the
change in discounted lifetime treatment costs and DALYs with and without intervention.
These estimates are based on published treatment cost and DALY estimates,
217
and are discounted at 3% per year. More details about the experimental scenarios are
provided in the appendix.
Sensitivity analyses with less ambitious programme coverage (5% vs 10% of the national
population per year), lower antiretroviral therapy uptake, and lower sensitivity and
specificity of screening for hypertension and diabetes are also presented in the appendix.
NCD=non-communicable disease. ART=antiretroviral therapy. DALYs=disability-adjusted
life-years.
Figure 16
Projected effects of HIV and NCD integration scenarios in Kenya
(A–B) The projected effect of the intervention on the number of new HIV infections
and AIDS deaths in Kenya in the next decade (2018–28). (A) Effects of the care cascade
in intervention communities in 2018, and similar patterns of improvement in cascades
are expected for each new set of intervention communities. (B) Improvements in care
cascades in 2018 averaged for the whole country. National care cascades are expected
to continue to improve through the end of programme in 2028. (C–D) The care cascades
for HIV, hypertension, and diabetes in adults before and after first year (2018) of
implementation in intervention communities and in Kenya, respectively. Intervention
communities constitute representative 10% of the adult population (aged ≥15 years),
with assumption of 90% screening uptake and treatment uptake after diagnosis of 81%
for HIV, 23% for hypertension, and 45% for diabetes. NCD=non-communicable disease.
ART=antiretroviral therapy.
Pairing NCD screening with HIV testing has important effects on the continuum of NCD
care. Immediately after the first year of screening campaigns, treatment in the intervention
communities increased from 10% to 47% for diabetes and from 8% to 27% for hypertension.
First year effects would be less dramatic at the national level, but the national
care cascades for hypertension, diabetes, and HIV will continue to improve as more
communities are covered under this programme. Over the ensuing decade, this integrated
screening and linkage-to-care intervention is projected to identify 686 000 individuals
with previously untreated diabetes and 7·57 million individuals with previously untreated
hypertension.
The per-person costs of the community health campaign are estimated at $21·03 for
community census and HIV testing and $1·19 for hypertension and diabetes screening,
all valued in 2016 $US. With an estimated 4·51 million individuals aged 15 years or
older who were screened in 2018, total costs for community mobilisation would be $56·8
million for HIV testing and $3·2 million for NCD testing. In 2018, the number of people
receiving ART would increase by 67 000 at an additional cost of $16·9 million, and
by 2028, 659 000 additional people would receive ART for $346·3 million in additional
treatment costs (assuming no further price reductions for ART). Through 2028, the
HIV-related components of the community health campaign would avert 6·5 million DALYs
at a discounted cost of $1480 million, equivalent to $227 per DALY averted, making
the intervention highly cost-effective relative to 2016 GDP per capita of $3155.
We estimate that 590 000 individuals with moderate or high blood pressure not currently
on treatment will be identified in 2018. Assuming an uptake of hypertension treatment
at 23%
215
and discounted incremental lifetime health-care costs of $149 and $486 for moderate-risk
and high-risk hypertension treatment, respectively, the hypertension screening and
treatment would avert 160 000 DALYs at a cost of $37·2 million, corresponding to $232
per DALY averted. Over the 10-year modelling scenario, the population would increase,
as would the costs and benefits, reaching $49·8 million and 215 000 DALYs averted
in 2028.
Assuming a prevalence of 2·2% for diabetes in adult Kenyans,
202
we estimate that blood glucose screening in conjunction with the HIV community health
campaign would identify 53 000 individuals with diabetes at a marginal cost of $54
per case identified, with this cost jointly shared by hypertension screening. With
standard glycaemic control for individuals with diabetes, the cost per DALY averted
is about $944.
218
As with the HIV-related components, the hypertension and diabetes components are estimated
to be highly cost-effective.
From a costing perspective, integrated programmes will probably be cost-effective
with respect to both HIV-related and NCD-related outcomes. From a policy perspective,
in the context of limited resources at the national level and competing interests
for allocation of available funding to different health sectors, integration of services
for HIV and NCDs offers a promising solution to diagnose HIV and NCDs. Nonetheless,
increased diagnosis will probably lead to increased demand for health-care services
in both Kenya and South Africa and will require substantial resources to meet the
demand.
Nigeria: integration of HIV with reproductive health services
With more than 3·2 million people infected with HIV, Nigeria has the second largest
HIV burden in the world. Unlike South Africa and Kenya, where more than 95% and 80%
of eligible women receive prevention of mother-to-child transmission (PMTCT) services,
respectively,
1
PMTCT coverage in Nigeria has stagnated at 30%, resulting in an estimated 75 000 new
infant HIV infections per year.
219
Similarly, only 15% of Nigerian women aged 15–49 years use contraception for limiting
and spacing of births. On average, a Nigerian woman gives birth to 6·5 children in
her lifetime. As 16% of currently married women have an unmet need for family planning
services, linking all married women who wish to space or limit their children to contraceptives
would increase the prevalence of contraceptive use to 31%.
220
The modelling scenario for integration of HIV and reproductive health services in
Nigeria is shown in panel 5
. In the absence of additional intervention, the baseline model estimates a 37% increase
in the number of women of reproductive age in the next decade (2018–28) because of
population growth, resulting in a growing need for family planning services in Nigeria.
Expansion of contraceptive use to 31% was estimated to result in a 15·5% reduction
in the total fertility rate (ie, from 6·5 children per woman at baseline to 5·49 children
per woman in 2028; figure 17
). This reduction in fertility would avert more than 8 million cumulative unintended
pregnancies between 2018 and 2028 when compared with a baseline level of contraceptive
use of 15%. Increasing PMTCT coverage to 90% of HIV-positive pregnant women in Nigeria
by 2023 is estimated to reduce the number of infants acquiring HIV by 56% (figure
17), averting more than 237 500 vertical HIV transmissions cumulatively in the next
decade. Expansion of PMTCT services along with family planning resulted in a further
estimated 12% reduction in HIV incidence at the national level, which is equivalent
to averting more than 295 500 new HIV infections by 2028 (figure 17) and a 3·5% reduction
in population-level HIV prevalence.
Panel 5
Modelling scenario for integration of HIV and reproductive health services in Nigeria
Spectrum's demproj, AIM/GOALs, and FamPlan modules were used to create three scenarios
describing integration of HIV and reproductive health services in Nigeria.
At baseline, the 2016 PMTCT coverage (about 26% of HIV-positive pregnant women) and
contraceptive use prevalence (15%) were maintained at fixed levels from 2018 through
2028. We further modelled the transition away from PMTCT Option B (provision of ART
during pregnancy and breastfeeding) by year 2020, and replaced that with an equal
coverage through Option B+ programmes (providing lifelong ART for all pregnant women
living with HIV).
For family planning, the prevalence of contraceptive use was scaled up linearly from
15% in 2018, to 31% in 2023 (to meet the unmet need for contraceptives by married
Nigerian women),
220
and was maintained at that fixed level until 2028.
For PMTCT, the proportion of HIV-positive pregnant women receiving ART through Option
B+ was scaled up linearly from 16% in 2016, to an ambitious target of 90% coverage
in 2023 (in accordance to UNAIDS and PEPFAR targets) for 95% PMTCT coverage
221
and was maintained at that target level until 2028.
For combined PMTCT and family planning, starting in 2018, both PMTCT coverage and
contraceptive use were scaled up linearly as described for each individual scenario
above.
To assess cost-effectiveness, PMTCT costs were based on PEPFAR estimates.
222
HIV-related treatment costs and DALYs were estimated as described for Kenya (panel
4). The effects of increased family planning access were estimated using the ImpactNow
model.
223
Family planning costs were based on a person-year cost of US$3·48 for a mix of contraceptive
methods. Per-user family planning costs ($3·48), maternal and infant health-care costs
averted ($3·15), and DALYs averted (0·35) were derived from the ImpactNow model.
PMTCT=prevention of mother-to-child-transmission. ART=antiretroviral therapy. DALYs=disability-adjusted
life-years.
Figure 17
Projected effects of HIV and reproductive health services integration scenarios in
Nigeria
(A) Total fertility rate. (B) Number of unintended pregnancies averted. (C) Number
of infants infected with HIV. (D) Cumulative number of new HIV infections in Nigeria.
Scenarios include expansion of family planning services by increasing the prevalence
of contraceptive use from 16% at baseline to 31% in 2023, and expansion of PMTCT by
increasing the coverage to reach 90% of HIV-positive pregnant women in Nigeria by
year 2023, compared against baseline levels in Nigeria. PMTCT=prevention of mother-to-child
transmission.
Increasing access to PMTCT would require $31·3 million in 2018, which includes $17·3
million in screening costs and $14·0 million in PMTCT costs. With full scale-up in
2023, $172·2 million would be required to identify and deliver PMTCT to an additional
142 000 HIV-positive pregnant women. Although the number of women receiving PMTCT
would decrease through 2028, the costs would increase slightly to $181·0 million because
of the larger number of pregnant women requiring screening as the prevalence of HIV
decreases. From 2018 to 2028, the scale-up of PMTCT would avert 8·6 million DALYs
at a cost of $169 per DALY averted and, compared with the GDP per capita of $5861
in 2016, would be highly cost-effective.
An increase in contraceptive use from 16% to 31% would require an additional investment
of $4·8 million in 2019, increasing to $27·4 million in 2023 with greater coverage
and population growth, and increasing further to $32·3 million in 2028 with continued
population growth. About 90% of the increased investments needed for scaled-up contraceptive
services would be offset by maternal and infant health-care costs averted through
family planning. 484 000 DALYs averted per year in 2019 would increase to 3·2 million
DALYs averted per year in 2028, with a total of 22·9 million DALYs averted. Increased
access to family planning is highly cost-effective and approaches the cost-saving
threshold, with a net cost of about $0·95 per DALY averted.
These results suggest that substantial improvements can be achieved by integrating
HIV and reproductive health services for women in Nigeria, averting, in the case of
HIV, more than 230 000 new infections in the next decade. A crucial first step for
ensuring the successful integration of HIV with reproductive health services is addressing
the underlying weaknesses of the existing health services in Nigeria because more
than a third of pregnant Nigerian women do not attend antenatal care services during
pregnancy,
224
with especially low coverage in poor, rural, currently married, and less educated
populations. Integration can aid in expanding the coverage of family planning services
in Nigeria, which in turn can avert a large number of unwanted pregnancies and unsafe
abortions.
India: Integrated management of HIV and sexually trainsmitted infections for men who
have sex with men (MSM) and female sex workers (FSW)
With more than 2 million people with HIV and an estimated 62 000 AIDS-related deaths
in 2016, India has the third largest HIV epidemic in the world.
1
Although most HIV transmissions are driven by heterosexual sex (accounting for 87%
of new infections in 2015), the epidemic is concentrated in high-risk groups, particularly
in FSW and their clients, MSM, and people who inject drugs in some sub-national settings.
In 2016, an estimated 2·2% of FSW in India had HIV, although there are considerable
geographic variations, with a prevalence in this population as high as 17·9% in Maharashtra
and 13·1% in Manipur in 2013. Similar variations are reported for other sexually transmitted
infections, with the prevalence of syphilis ranging from 3·1% to 51·0% for FSW and
from 3·5% to 28·0% in MSM and transgender people.
225
India is committed to the prevention and control of epidemics of sexually transmitted
infections and HIV. The Avahan initiative is estimated to have averted 202 000 HIV
infections in 4 years.
226
Respondent-driven sampling has been used to engage MSM and people who inject drugs
in testing services for sexually transmitted infections and HIV in India.
227
In addition to expanding the reach of these screening and prevention programmes, integration
of sexually transmitted infections and HIV can also facilitate linkage to, and engagement
in, HIV care through a combination of medical, social, and economic interventions
targeting key populations. We applied the Spectrum model to estimate the epidemiological
and economic effect of such an approach on outcomes related to HIV and sexually transmitted
infections in MSM and FSW in India (panel 6
).
Panel 6
Modelling scenario for the integration of HIV and sexually transmitted infections
in India: MSM and FSW
The Spectrum package was used to model HIV transmission in MSM and FSM in India. An
intervention scenario was modelled to represent integration of services for HIV and
sexually transmitted infections for these populations.
At baseline, ART coverage was maintained at the estimated 2016 level from 2018 to
2028.
Using data from the Avahan programme, we modelled a joint community-outreach campaign
for HIV and sexually transmitted infection screening in MSM over a 5-year period (2018–23).
On the basis of reported levels of population coverage from Avahan, we assumed that
this programme could reach 60% of MSM and 90% of FSM and will provide an infrastructure
for maintaining all improvements in HIV treatment and PrEP coverage over the subsequent
5 years (2024–28). To model the potential effect on HIV-related outcomes, we assumed
that this integrated intervention can successfully deliver ART to 81% of individuals
with diagnosed HIV who are not currently receiving HIV treatment (ie, 90% linkage
and 90% engagement). This corresponds to a 54% and 81% reduction in the unmet need
for ART in HIV-positive MSM and FSM, respectively. We modelled this effect as a linear
increase in the rate of ART coverage from 2018 to 2023. Furthermore, to estimate the
potential effect of PrEP, we modelled two additional scenarios for implementation
of oral PrEP in these two populations at low (10%) and high (30%) levels of coverage.
In these scenarios, PrEP coverage was increased linearly from 2018 to 2023 (continuing
at fixed levels through 2028), and PrEP adherence was assumed at 50% for those individuals
on PrEP.
Because of a lack of representative data on the incidence and prevalence of sexually
transmitted infections in these two populations, we limited our analysis to study
the effect of integrated programmes for screening and treating syphilis infection.
Moreover, because of the complexity of modelling the co-epidemics of syphilis and
HIV infections in India, we chose a simplified approach for estimating the effect
of the intervention on programme participants only and did not estimate the effect
on secondary infections averted. Using an array of available estimates from the scientific
literature, we estimated the national prevalence of syphilis at 5·8% of FSW and 3·5%
of MSM (appendix).
Following the methodology proposed by Solomon and colleagues,
227
we modelled a scenario for reaching these two populations through respondent-driven
sampling, whereby members of these populations are incentivised to visit programme
sites and refer others to programme sites, at an estimated cost of US$20·33 per person
tested. ART costs were estimated at $126·06 per person-year. PrEP costs of $91 per
person-year were based on Stover,
228
with updated drug cost estimates for tenofovir disoproxil fumarate plus lamivudine.
229
Syphilis testing and treatment costs for FSW and MSM were estimated at $3·50 and $9·30,
respectively.
230
DALYs per prevalent syphilis case (0·64) were calculated using the method by Korenromp
and colleague,
230
using estimates of the global DALYs for syphilis
231
and the global prevalence of syphilis.
232
MSM=men who have sex with men. FSW=female sex workers. ART=antiretroviral therapy.
PrEP=pre-exposure prophylaxis. DALYs=disability-adjusted life-years.
The integrated intervention is projected to gradually increase coverage of ART in
the next 5 years, reaching coverage of 73% of MSM (compared with 43% at baseline)
and 81% of FSW (compared with 29% at baseline). This corresponds to an additional
1 180 000 person-years on ART in the next decade. Through this intervention, the number
of new HIV infections in MSM is projected to fall by 34% by 2028, corresponding to
43 000 new infections averted (figure 18
), and 59 000 AIDS-related deaths will be averted. Given the projected rapid decrease
in HIV incidence in FSW at baseline, the intervention is estimated to reduce HIV incidence
only marginally (1·6% reduction in 10 years) but AIDS-related deaths substantially
(by 81%), averting 6200 deaths in FSW. At a national level, this intervention reduces
the number of new transmissions in the population by 7%, averting 51 000 new infections
and 81 000 AIDS-related deaths in the next decade. In sensitivity analyses with 40%
(vs 81%) uptake of ART, HIV incidence was roughly halved, with HIV incidence falling
by 17% in MSM, by 0·4% in FSW, and by 3·2% at a national level.
Figure 18
Projected effects of HIV and sexually transmitted infection services integration scenarios
for MSM and FSW in India
The number of new HIV infections in (A) MSM and (B) FSW. Intervention scenarios include
expansion of ART coverage in MSM (from 43% to 73%) and FSW (from 29% to 81%) with
no PrEP, at a low PrEP coverage of 10%, and at a high PrEP coverage of 30%. Each scenario
is modelled as a gradual increase in coverage of ART and PrEP in MSM and FSW from
2018 to 2023, continued at a fixed coverage afterward (2024 to 2028). MSM=men who
have sex with men. FSW=female sex workers. PrEP=pre-exposure prophylaxis. STI=sexually
transmitted infections.
Implementation of PrEP will further improve the epidemiological outcome, although
the extent of PrEP-related benefits is limited by the preventive effects of expanded
ART coverage. For example, provision of PrEP at a low-coverage or high-coverage level
(corresponding to more than 11·1 million and 33·6 million person-years of PrEP from
2018 to 2028, respectively) will avert 6800 and 20 000 additional new HIV infections
in MSM and FSW compared with ART scale-up alone. With respect to other sexually transmitted
infections, the integrated HIV–syphilis programme is projected to diagnose and treat
more than 510 000 cases of syphilis in FSW (5·8% prevalence) and MSM (3·5% prevalence)
in 2018 alone. The number of cases detected and treated in subsequent years will depend
in part on the rate of infection and reinfection in individuals who were previously
treated.
In the intervention scenarios, recruitment and HIV testing and referral costs would
increase from $34·1 million in 2018 to $190·4 million in 2028. With 81% uptake of
ART by individuals who are diagnosed, the number of people receiving ART would increase
over the baseline by 55 000 in 2018 and by 107 000 in 2028. Excluding PrEP, the programme
of testing and treatment would be highly cost-effective, averting 2·7 million DALYs
at $656 per DALY averted (per-capita GDP of $6571 in 2017), with an incremental cost
of $1797 million over the base-case cost of $1·315 million. Neither of the PrEP scenarios
(10% or 30% coverage) would be cost-effective, with an incremental cost of $21 531–58 812
per DALY averted compared with the no-PrEP scenario.
The addition of syphilis screening and treatment to the HIV testing and treatment
(but no-PrEP) scenario would probably be highly cost-effective. In 2018, the programme
would test 1·68 million individuals and diagnose and treat 76 000 cases at an incremental
cost of $6·6 million. At an estimated 0·64 DALYs per prevalent case, we estimate that
this scenario would avert 49 000 DALYs in the first year at $135 per DALY averted.
Our results suggest that the modelled interventions would lessen the burden of HIV
and syphilis infection in MSM and FSW in India. Increasing the coverage of ART in
MSM to 54% would avert substantial numbers of new HIV infections and AIDS-related
deaths. Further addition of PrEP can provide marginal improvements in HIV-related
outcomes, although the population-level implementation of PrEP in these populations
in India is not cost-effective. As suggested by previous studies, PrEP should be tailored
to high-risk populations who stand to benefit the most from it. On the other hand,
despite assuming a higher level of achievable coverage in FSW (up to 90%), similar
programmes resulted in smaller improvements to HIV incidence over time in this population,
primarily stemming from the decreasing prevalence of HIV in FSW in India. Integrated
programmes provide an opportunity for mass screening and treatment of other sexually
transmitted infections, including syphilis. Even ignoring the potential effect for
averting future syphilis transmissions and reducing the transmissibility of HIV infection
in coinfected cases, the integrated programme was cost-effective.
Our results for these scenarios in India are limited by several restricting assumptions.
First, we excluded the existing geographical heterogeneities in patterns of the prevalence
of sexually transmitted infections and HIV in key populations in India (as evident
by a wide range of reported HIV prevalences in MSM, ranging from 2·5% in Tamil Nadu
to 14% in Andhra Pradesh in 2016), which can have important implications for the estimated
effect and costs of integrated programmes in different part of the country. Future
research could build on our findings by investigating the effect of integration in
various Indian cities and states representative of different epidemiological profiles
and health-system infrastructures. Furthermore, our simplified approach to estimating
the effect of intervention on sexually transmitted infections is limited by restricting
assumptions that might under-estimate the effect of interventions on the sector. Future
studies applying transmission models of HIV–sexually transmitted infection co-epidemics
in India might provide more representative estimates of epidem-iological outcomes.
Russia: integrated harm reduction and ART for people who inject drugs
An estimated 1% of the Russian population has HIV, but the prevalence of HIV is much
higher in people who inject drugs, with city-level estimates for this population ranging
from 3% to 64%.
233
Several regions in the Ural and Siberian Federal Districts have the highest incidences
of new HIV diagnoses in the country, most of which are in people who inject drugs.
76
People who inject drugs in Russia are also at high risk of overdose (estimated at
2 overdoses per 100 person-years).
234
Although harm reduction and HIV treatment services would clearly benefit the country's
estimated 1·88 million people who inject drugs, considerable barriers prevent these
services from being scaled up. Non-naltrexone MAT remains illegal, despite evidence
that it reduces HIV transmission risk,
235
fatal overdose,
236
drug-related criminal behaviour,
237
and discontinuation of ART;
238
and NSPs are legal but badly underfunded, providing on average only 1–3 syringes per
person who injects drugs annually.
115
Coverage of ART in people who inject drugs is low,
239
with evidence of denial of therapy to active users of drugs in some settings,
240
and 2017 Russian clinical guidelines recommend possibly delaying treatment initiation
in patients with evidence of severe drug addiction,
241
which could act as a barrier for the scale-up of ART in people who inject drugs.
We examined the effect of policy changes enabling the expansion of integrated harm
reduction and HIV services on HIV and fatal overdose among people who inject drugs
in two Russian settings. A dynamic transmission model of HIV among people who inject
drugs (panel 7
) was developed to assess the effect of scaled-up harm reduction (NSP or non-naltrexone
MAT, or both), alone or integrated with scaled-up ART for people who inject drugs.
For illustrative purposes, we modelled two different HIV epidemic settings (figure
19
): (1) Omsk, a major city in the Siberian Federal District with evidence suggestive
of a growing epidemic; and (2) Ekaterinburg, Russia's fourth largest city located
in the Ural Federal district with a stable and high-prevalence epidemic in people
who inject drugs.
Panel 7
Modelling methods: integrated harm reduction and ART in Russia
We used a dynamic epidemic model of HIV in people who inject drugs to assess the potential
effect of integrated harm reduction and HIV services for this population in Russia.
Full methodological details are in the appendix.
A dynamic and deterministic model of HIV transmission in this population was developed,
incorporating injecting and sexual transmission in people who inject drugs. People
who inject drugs enter due to injecting initiation and exit due to cessation of injecting
or death (overdose, HIV-related death, or non-HIV background mortality). The model
was stratified by HIV disease stage (uninfected, acute, latent, pre-AIDS, AIDS), ART
status, risk (low or high, defined as history of incarceration on the basis of survey
data for both settings), sex, and harm reduction access (off or on). We assumed no
baseline coverage of any harm reduction and minimal ART coverage (26% of HIV-infected
people who inject drugs in 2014). We modelled harm reduction scale-up through exploring
different scenarios of harm reduction programme availability: high coverage NSP only,
non-naltrexone MAT only, or combined NSP and MAT service, either alone or integrated
with expanded ART for people who inject drugs. NSP and non-naltrexone MAT were assumed
to reduce injecting-related HIV transmission risk. Non-naltrexone MAT was additionally
assumed to increase ART recruitment rates, reduce treatment drop-out, and reduce rates
of fatal overdose. However, we also incorporated increased mortality risk within the
first 4 weeks of MAT initiation and discontinuation. ART was assumed to reduce HIV-related
mortality, as well as sexual and injection-related transmission.
The model was calibrated to two cities with differing epidemic profiles in Russia:
Omsk (high but expanding HIV epidemic in people who inject drugs) and Ekaterinburg
(very high but stable HIV epidemic). For each setting, the model was calibrated to
multiple timepoints of HIV prevalence in people who inject drugs, stratified by sex
and risk (incarceration history, when available), ART coverage in 2014, proportion
high risk (ever incarcerated), and the estimated proportion of transmission related
to sexual risk. Because of uncertainty, most parameters were sampled from underlying
distributions, generating 100 parameter sets. For each parameter set, the model was
calibrated to the data using an optimisation solver and minimising the sum log likelihood.
For each of these 100 calibrated parameter sets, model scenarios were run and projections
presented as means and 2·5–97·5% intervals.
We examined the effect of the following intervention scale-up scenarios: (1) no harm
reduction base-case; (2) NSP for 50% of people who inject drugs; (3) MAT for 25% of
people who inject drugs; (4) MAT for 50% of people who inject drugs; (5) combination
NSP–MAT for 50% of people who inject drugs; and (6) combination NSP–MAT for 50% of
people who inject drugs integrated with scaled-up ART for HIV-infected people who
inject drugs on harm reduction (recruited at three times current rates). We tracked
the effect on HIV infections and fatal overdoses in people who inject drugs. The percentage
of new HIV infections and fatal overdoses in people who inject drugs averted in the
next decade was calculated by comparing the cumulative projected number of events
from 2018 to 2028 with intervention scale-up compared with the base-case.
ART=antiretroviral therapy. NSP=provision of clean needles and syringes. MAT=medication-assisted
therapy. HCV=hepatitis C virus.
Figure 19
Model projections of the effect of integrated harm reduction and HIV services in two
Russian cities
Model projections of (A) median HIV prevalence in PWID in Omsk, Russia, (B) median
HIV prevalence in PWID in Ekaterinburg, Russia, (C) proportion HIV infections averted
in PWID in 2018–28, and (D) proportion of fatal overdoses averted in PWID in 2018–28
with various levels of intervention scale-up. Scenarios include no harm reduction
or ART (base case), expansion of NSPs to 50% coverage in PWID (NSP 50%), expansion
of MAT to 25% or 50% of PWID (MAT 25%; MAT 50%), combination MAT and NSP to 50% of
PWID (MAT+NSP 50%), or combination MAT and NSP to 50% of PWID integrated with ART
recruited at three times the base-case recruitment rate of HIV-infected PWID on harm
reduction per year from 2018. Observed HIV prevalence data in PWID shown as black
circles and 95% CI; dashed lines are 2·5–97% uncertainty bounds. Box plots indicate
the median (middle line) projections, 25–75% percentile range (boxes), and 2·5–97·5%
percentile range (whiskers), and median estimates reported above box plots. PWID=people
who inject drugs. ART=antiretroviral therapy. MAT=medication-assisted therapy. NSP=needle
and syringe programme.
Removal of structural and funding barriers in harm reduction provision could have
a substantial effect on both HIV and fatal overdose. Expanding high coverage NSP to
50% of people who inject drugs could avert 36% (2·5–97·5th percentile 15–51%) and
23% (7–33%) of new HIV infections in people who inject drugs in the next decade in
Omsk and Ekaterinburg, respectively (figure 19). A legal change allowing non-naltrexone
MAT would avert both HIV infections and prevent fatal overdose. Scaling up non-naltrexone
MAT to 50% coverage could avert 36% (2·5–97·5th percentile 21–49%) and 21% (11–29%)
of HIV infections in Omsk and Ekaterinburg, respectively, and prevent about 32% (26–37%)
of fatal overdoses in 10 years in Omsk and Ekaterinburg. About half the effect on
HIV and overdoses would be achieved if MAT were only scaled-up to 25%. In combination,
scale-up of MAT and NSP at 50% coverage could avert 48% (2·5–97·5th percentile 28–60%)
and 33% (23–39%) of HIV infections in people who inject drugs at 10 years in Omsk
and Ekaterinburg, respectively.
Scale-up of combination MAT plus NSP to 50% of people who inject drugs and integrated
ART (recruiting HIV-infected people who inject drugs in harm reduction at three times
the current recruitment rates) would avert 53% (2·5–97·5th percentile 40–65%) and
36% (25–45%) of new HIV infections in 10 years in Omsk and Ekaterinburg, respectively.
Given the paucity of existing HIV prevention services for people who inject drugs,
the economic implications of the expansion scenarios described are uncertain. However,
methadone is cost-effective in neighbouring Ukraine
242
and Kazakhstan,
243
at an estimated annual cost of US$250–415 per person who injects drugs (2017 US$).
During the period when the Global Fund invested in HIV programmes in Russia, the cost
per needle exchanged in the country was $0·38.
244
Scaling up MAT and NSPs to 50% of the 1·88 million people who inject drugs in Russia
could cost $333–521 million annually. Additionally, the cost of ART regimens varies
from $3050–4290 per year in Russia,
245
and modelling has predicted ART provision for people who inject drugs would be cost-effective
in Russia.
Our work supports findings from previous studies, which indicate that removing policy
and programmatic barriers and expanding HIV and harm reduction services to people
who inject drugs in Russia would have a substantial effect on HIV,
246
and reveals marked benefits in preventing fatal overdose. Our analysis does not take
into account likely additional benefits that scaled-up harm reduction services would
have on preventing HCV transmission or recidivism, which are likely to be substantial,
as an estimated 69% and 40% of people who inject drugs in Russia have a history of
HCV infection and incarceration, respectively.178, 247, 248
These modelling exercises show multiple health benefits that could be achieved through
integrating services for HIV and other health conditions, and they also highlight
the crucial need for setting-specific approaches to integration. In settings such
as Kenya and South Africa, with generalised HIV epidemics and increasing burden of
underdiagnosed and undertreated NCDs, integrated community-based screening could yield
substantial benefits in identifying and treating hypertension, diabetes, and HIV.
The realisation of such benefits, however, will be limited by the capacity of the
health-care system to provide appropriate treatment. In settings like Nigeria with
low antenatal care coverage and substantial mother to child HIV transmission, integration
of PMTCT and family planning services could reduce HIV infections in infants and in
the population as a whole as well as prevent unintended pregnancies. Increasing PMTCT
coverage will require both access to and uptake of care. The former might require
substantial infrastructure and human resources investments, and the latter could benefit
from scale-up of peer support or congregation-based interventions.
In countries with concentrated epidemics in FSW and MSM, integrating testing and treatment
for sexually transmitted infections and HIV should be considered. Modelling in India
suggests that this approach would be cost-effective in addressing HIV and syphilis
infections in both sex workers and MSM. Although we have modelled a streamlined approach,
a more comprehensive intervention such as Avahan could prove more cost-effective.
In some countries, few or no services are available for integration for highly affected
populations. For example, in Russia, where there is a high concentration of HIV in
people who inject drugs, the harm reduction, drug treatment, and HIV services for
this population are either illegal or reach few in need. As such, there is an urgent
need in Russia first for legal changes and capacity building to provide basic health
services for people who inject drugs, ideally in an integrated programme that could
reduce HIV, HCV, fatal overdose, and mass incarceration. Future work should consider
the optimal integration strategy in each country based on HIV epidemiology and the
health-care system, and models of integration will be improved through increased understanding
of barriers and facilitators of integration and will depend on how well different
integration scenarios can achieve economies of scope and scale. The potential benefits
of integration are substantial, but they are only realisable with the bridging of
now-siloed health-care strategies.
The future of global health and HIV: governance and financing
Capturing and sustaining the benefits of a more integrated approach to HIV and global
health, as demonstrated in the Commission's modelling studies, will demand governance
approaches that enable the world to give health the priority it deserves. Additionally,
substantial, new, and reliable financing will be necessary to lay the foundation for
sustainable health for all.
Governance for sustainable global health
The path towards a robust governance system for global health suitable for the era
of sustainable health and development will inevitably be complicated, involve diverse
stakeholders, and require honest dialogue about the strengths, weaknesses, and value
added of all actors that have a role in health governance. For the new era of global
health solidarity, a review of governance architecture is warranted. New institutional
frameworks or approaches might be needed to elevate health as a central global priority
and to usher into place comprehensive, integrated, and people-centred health systems
that provide universal health access. To this end, the Commission urgently calls for
an independent effort, authorised by an appropriate resolution of the UN General Assembly,
to outline new institutional architecture and arrangements to carry forward the new
era of global health solidarity envisaged by the Commission. A similar approach has
been used before, when a UN resolution authorised the deliberative process that resulted
in the closure of the WHO Global Programme on AIDS and the launch of UNAIDS.
84
As a key component of the work of this independent governance review, actionable recommendations
should be developed to make HIV governance less duplicative and costly and optimally
accelerate progress toward ending the pandemic.
HIV and health governance
The HIV response arguably has the best developed mechanisms for governance of any
aspect of the global health agenda. The institutional governance structure for HIV
was developed rapidly, beginning in the mid-1990s at the global level, in response
to the recognition of HIV as a global health emergency. Key actors in the pluralistic
HIV governance approach include national health ministries, participatory national
coordinating bodies (eg, national and provincial AIDS councils, country coordinating
mechanisms), international governance bodies (eg, UNAIDS Secretariat and Cosponsors,
including WHO), key donors (eg, Global Fund, PEPFAR, Bill & Melinda Gates Foundation,
and other philanthropic entities), and organisations that focus on specific HIV priorities
and functions (eg, Unitaid for market-shaping, Medicines Patent Pool for the issuance
of voluntary licensing).
HIV governance includes elements that can inform the evolution of global health governance
more generally, including its engagement of civil society and affected communities,
institutional emphasis on a multisectoral response, and ethos of mutual accountability
for achievement of concrete targets. HIV remains unusual within the global health
field with respect to the extent of its formalised engagement with civil society (figure
20
). Global health governance will be more responsive, effective, and politically potent
if it includes strong participation from diverse non-governmental stakeholders. The
greater integration of affected communities in global health governance, should it
occur, will be one of the lasting legacies of HIV activism.
Figure 20
Community-led prevention providing combination prevention including pre-exposure prophylaxis
to their peers in Thailand
Credit: © Richard Nyberg, USAID.
However, the HIV experience also offers warning signs, as governance of the HIV response
over time has become bloated and overly costly. The elaborate mechanisms for governance
of the HIV response have not prevented a premature withering of commitment to the
HIV fight. In addition to clearly outlining an overarching global health governance
architecture, the independent panel proposed by the Commission should also examine
how best to ensure that HIV governance is fit for the purpose of meeting current challenges
and galvanising a sustainable response for the long term. Making HIV governance leaner,
focusing governance on the overriding challenge of rebuilding political support and
financing for HIV, and reviving African solidarity and leadership on HIV will be pivotal
to hopes for rejuvenating the response.
Although efforts to strengthen governance of certain aspects of global health are
growing, as reflected, for example, in the Third High-Level Meeting on NCDs planned
at the UN in 2018, the gap in governance between HIV and non-HIV-related health issues
is considerable. Neither NCDs, maternal and child health, nor any other single disease,
for example, has advocacy benefits, partnership cultivation, and focused governance
structure that is comparable to what UNAIDS brought to the HIV response. By contrast
with HIV, key weaknesses of the global fight against cancer and other NCDs include
the lack of strong global leadership and an inclusive social movement.
249
The new governance approach for a new era of global health solidarity must include
both overarching governance structures that address health-system weaknesses and promote
comprehensive approaches that integrate services for diverse health conditions as
well as sufficiently resourced and high-visibility disease-focused advocacy and governance
structures to drive progress against the leading causes of death and disability (eg,
cancer, cardiovascular disease, maternal and child health, tuberculosis).
The multidimensional governance structure developed for HIV includes key functions
that will be required to ensure sustainable health for all. For example, the Global
Fund is a highly successful platform for pooling resources for results-driven national
programmes for HIV, tuberculosis, and malaria. Likewise, outside the HIV arena, GAVI,
the Vaccine Alliance has had a pivotal role in increasing the rates of childhood immunisation
250
by pooling and distributing resources for vaccination programmes in resource-limited
settings. To accelerate health access and achieve the ambitious health aims of SDG
3, one or more similar mechanisms will be needed to mobilise, pool, and distribute
resources for health systems strengthening, universal and equitable access to health
commodities, and programmes to address priority health conditions such as NCDs and
sexual and reproductive health.
Market-shaping measures will be needed to facilitate access to affordable medicines,
vaccines, and diagnostics. In the case of HIV, the Medicines Patent Pool issues voluntary
licenses for the generic manufacture of priority medicines, whereas Unitaid undertakes
market-shaping interventions to enhance the affordability and uptake of essential
interventions. To achieve worldwide expansion of access to health commodities to treat
other leading causes of deaths, these market-oriented functions must extend well beyond
HIV. To date, the voluntary licensing route has been used for HIV medicines and recently
for direct-acting antivirals for HCV but not for medicines to treat cancer, hypertension,
diabetes, or other diseases.
A sound health system is necessary but not sufficient for ending the HIV epidemic.
Although opportunities for synergies and greater integration must be seized, categorical
programmes and a dedicated governance system will remain essential if the world hopes
to make good on its many HIV commitments.
Towards sound governance for sustainable health: key principles
Governance mechanisms must ensure that communities and broader civil society are fully
engaged as partners in the conceptualisation, implementation, and monitoring of people-centred
health systems. Health governance must strive for equity in access to global health
goods and in health outcomes. Ushering in an era of genuine global health solidarity
will demand a shared understanding of global health as a common enterprise, with institutional
governance arrangements that are inclusive, democratic, and take into account the
perspectives of all stakeholders.
Governance mechanisms for health must be sufficiently resourced, transparent, and
accountable. Health governance should be multidisciplinary to ensure appropriate attention
to social and structural factors and to promote integrated and coordinated approaches
to multiple health challenges. Governance for health must be forward-looking and build
capacity at national, global, and regional levels to anticipate and respond to future
problems such as health emergencies or national transition from eligibility for international
assistance. Transitions away from international support must be undertaken over a
reasonable period of time (at least 10 years), and flexibility in transition approaches
will be essential, enabling course corrections if and when problems arise (such as
the collapse of community service systems for marginalised groups). Eligibility for
international assistance should continue for countries with limited domestic capacity,
heavy disease burden, and high-prevalence, high-incidence settings or populations.
Consistent with the vision of sustainable health for all, global health governance
must ensure prioritised attention to the most susceptible and marginalised people.
Global health governance must reflect and promote principles of human rights and gender
equity. The new era of global health solidarity will demand governance mechanisms
that elevate scientific evidence over ideology. Effective health governance evinces
a willingness to speak hard truths when necessary.
Effective health governance functions as a faithful steward of public resources, implementing
measures to protect against corruption, diversion of resources, and conflicts of interest.
Effective health governance also inevitably depends on sound governance more generally,
underscoring the need for countries to adhere to principles of democracy, open societies,
inclusive and participatory processes, transparency, and accountability.
Financing for sustainable global health
Achieving universal health coverage will require substantial resources over and above
amounts presently spent on health.
251
For both HIV and global health generally, a continuation of current trend lines in
financing will leave the world without sufficient resources to achieve the ambitious
health targets of SDG 3.5, 252, 253
A new era of global health solidarity is needed, augmenting and fully synergising
the contributions of each essential financing sector (eg, national governments, the
international community, and the private sector) and continually reinforcing health
investments as central to the international development agenda. Key to this era of
global health solidarity will be rapid creation of a reliable, sustained mechanism
for the equitable distribution of global public goods supported by global-level mechanisms
to generate and pool resources.
As the decision to allocate resources inevitably reflects political choices, a political
sea change is needed if the financing required to control communicable diseases and
to effectively manage NCDs is to be mobilised. Drawing on experiences from the 1990s
and early 2000s, when the world was jolted out of its early and lethargic response
to the HIV epidemic, the HIV community must urgently join together to focus the world's
attention on the very real risk that we will lose the fight against HIV without major
new investments. African leaders, in particular, must become broadly re-engaged in
rejuvenating the HIV response because failure risks undermining the sustainable development
agenda. Together, the HIV community and the broader global health field must undertake
a comprehensive advocacy effort to position health as central to the broader global
development agenda.
Domestic resources, which already finance most of health spending in LMICs, must serve
as a cornerstone of financing in the era of sustainable health.
254
Health spending, both per capita and as a share of GDP, is increasing in LMICs, increasing
faster than the economy as a whole in the past 15 years.
254
However, per-capita amounts spent on health in some LMICs are too low to deliver even
the most basic package of health services,
255
and the failure of most African countries to meet the Abuja Declaration target for
health spending highlights the need for greater domestic investments and political
support for health. Economic growth offers an opportunity for many LMICs to increase
investments in health,
4
but national leaders must demonstrate sufficient political will to allocate these
dividends to health services. A recent analysis by the Global Burden of Disease Health
Financing Collaborator Network
4
found per-capita health spending in Bangladesh and Pakistan would roughly triple and
double, respectively, were these countries to allocate towards health the share of
national budget spent by similarly situated countries that place greater priority
on health. Realisation of the vision of sustainable health for all will require LMICs
to dig much deeper into their own pockets, and the World Bank and regional development
banks must aid by expanding incentives to invest in health. To maximise domestic financing
for health, systematic efforts are needed to avoid inefficiencies linked to the diversion
of scarce resources through rent-seeking, clientelism, and corruption and to increase
the accountability of national and subnational governments.
Universal health coverage can aid in off-loading certain health-related costs from
the public sector and better enable public programmes to target services for the most
susceptible communities. Although categorical HIV funding will remain essential for
the foreseeable future to rejuvenate the response, funding for HIV programmes over
time should progressively be integrated into broad-based social insurance systems,
pooling resources through prepayment mechanisms, and innovative funding methods will
be needed to incentivise integrated and multidisease approaches.
Careful planning and bridge funding are essential for an effective transition from
donor dependence to national funding. However, the reality for the foreseeable future
is that many countries, irrespective of whether bridge funding is available, are unlikely
on their own to finance programmes that benefit marginalised populations that are
politically powerless and that, in some cases, are subject to official harassment,
institutionalised discrimination, and criminalisation. Both for HIV and for other
priority health issues, the international community must continue to support essential
prevention and treatment programmes for populations that would otherwise be left behind.
In addition to increased domestic financing, the new era of global health solidarity
will require more, not less, engagement of the international community to foster collective
action. In particular, robust international support for health will be essential to
fund public goods, address cross-border health issues, and address health needs in
low-income countries, where per-capita health spending, fiscal space, and health-system
capacity will remain limited.4, 252 Africa accounts for the overwhelming majority
of low-income countries that will continue to need extensive international health
assistance.
The pivotal role of international donors in jump-starting the global HIV response
has been widely heralded, but the reality is that high-income countries remain parsimonious
with respect to global health and development assistance. Although developed countries
have pledged to allocate 0·7% of gross national income to development assistance,
in 2015, only six countries (Denmark, Netherlands, Norway, Luxembourg, Sweden, and
the UK) reached this target.
256
Official development assistance for health is projected to increase only marginally
through 2030,
4
and concern with recent reductions in international HIV assistance is growing.
Renewing the engagement of the international community on health issues will require
new thinking and prioritisation by international decision makers. The growth in antimicrobial
resistance
257
and increasing concerns about the global capacity to respond to health emergencies
are reminding international donors of their own stake in having strong and durable
health systems in place in all countries. New political leadership in countries such
as Canada, France, and South Africa offers opportunities to revive political support
for global health.
Consistent with the Commission's findings, financing efforts in the new era of global
health solidarity must achieve two aims: follow through on commitments made on HIV
and mobilise sufficient resources to build strong, durable and people-centred health
systems; and achieve universal health access. A robust and well funded Global Fund
will be essential to hopes for achieving major progress in reducing new cases of HIV,
tuberculosis, and malaria and associated mortality from all three diseases, and similar
mechanisms will be needed to finance health-systems strengthening and service integration
and to focus efforts on preventing leading global causes of death.
The USA is by far the largest single donor for health assistance, although in other
countries such as the UK, the proportion of GDP devoted to health assistance is greater
than the USA.
258
Although the Trump administration has proposed major reductions in international health
assistance, it is heartening that a bipartisan coalition in the US Congress has rejected
these proposed cuts and confirmed US leadership on global health. In the omnibus budget
approved in March, 2018, for the fiscal year 2018, Congress provided 34% more funding
for global health assistance than requested by President Trump, holding steady funding
for PEPFAR and the Global Fund and increasing appropriations for global health security.
The US Government should maintain support for PEPFAR as a singular contribution to
global health and wellbeing. In particular, US decision makers should move beyond
the singular focus on achieving epidemic control in its 13 priority countries, especially
as feared funding cuts to PEPFAR have not materialised. As a shared global responsibility,
financing for health will require greater engagement by the EU and cultivation of
major new donors such as China.
The future of global health and the HIV response: recommendations for sustainability
Creating people-centred health systems that ensure universal access to essential health
services will demand concerted action by the entire global community. Only a genuine
global movement, engaging diverse communities, linking together the HIV community
and the global health field, and uniting multiple sectors in a common undertaking
to improve the health and wellbeing of all people can realise the vision of sustainable
health for all. Towards realisation of this vision, the Commission offers the following
recommendations for immediate action.
1
The world must take immediate steps to rejuvenate the HIV response and follow through
on its HIV-related commitments
All HIV stakeholders must join together to revitalise the HIV response, recognising
both the urgency and the long-term nature of the global fight against HIV. Towards
averting a potential resurgence of the epidemic, the reduction in HIV categorical
funding, including major new investments by domestic governments and international
donors, must be reversed.
HIV prevention must be revitalised and brought to scale. Whereas redoubling efforts
to maximise the preventive and therapeutic benefits of ART through achievement of
the 90-90-90 benchmarks, national governments, international donors, and HIV advocates
must place much higher priority on primary HIV prevention to avert a resurgence of
the epidemic. Communities should be resourced to lead prevention efforts, and stronger,
prioritised investments in research are needed to accelerate progress towards the
development of a preventive vaccine and a cure for HIV.
2
HIV should be carefully and strategically integrated within primary care and the broader
global health agenda, with the scale and pace of integration geared to national and
subnational circumstances and the needs of the populations in greatest need of HIV
services
Immediate efforts are required to integrate HIV services with services for diseases
that clearly overlap or are closely linked with HIV, and strengthened integration
of contraceptive services, maternal child heath, and women's sexual health and reproductive
rights, which is cost-saving and of vital importance to women's health, is urgent
for successful control of perinatal transmission of HIV. Co-located and client-centred
primary care services (one-stop shopping) should be scaled up. Effective integration
will involve both the integration of HIV interventions in mainstream primary care
and other service systems as well as the leveraging of HIV service systems for the
co-located integration of other health services.
Effective integration of HIV with broader health systems is only possible if key defining
features of the HIV response are preserved and mainstreamed; these include a respect
for human rights and gender equality, sufficiently resourced participatory mechanisms
for community inclusion and engagement, an ironclad commitment to ensure equitable
access and to leave no one behind, and multisectorality to address the social and
structural determinants of health
Population-focused service integration should be prioritised to address the needs
of underserved populations. Adolescents of all genders and sexual orientations need
adolescent-friendly information and services that are relevant, comprehensive, and
address their sexual and HIV risks in a broader framework that is focused on their
wellbeing, rights, and needs. Especially in settings where marginalised populations
are not well served by mainstream health services, integration and co-location of
services for these populations is urgently needed to enhance access to good-quality
and culturally appropriate care and support. Notably in Russia and the wider eastern
Europe and central Asian region, and any other setting where substantial injecting
opioid use occurs, immediate efforts are needed to scale-up and integrate harm reduction
services, overdose prevention, evidence-based drug treatment, and HIV, tuberculosis,
and HCV services for people who inject drugs.
Efforts to integrate the HIV response more broadly into national health systems should
be undertaken thoughtfully and follow careful study. Models should be used to predict
the effects and cost-effectiveness of service integration scenarios.
Additional financing will be necessary to sharply reduce new HIV infections. Robust
financing of the Global Fund and continuation of PEPFAR will be crucial to future
prospects for reducing new HIV infections and AIDS-related deaths. Categorical HIV
funding will remain essential for the foreseeable future and while transiting toward
greater integration, although incremental steps should thoughtfully incorporate HIV
funding over time into broader health insurance schemes. Innovative formulae to fund
co-located, multidisease, and integrated services should be explored immediately.
No one must be left behind in the HIV response. All countries, including upper-middle-income
and high-income countries, must accept the responsibility to provide life-saving services
for all segments of their population, but in cases where countries fail in this responsibility,
strong and flexible international mechanisms must be available to fund community-based
services for marginalised groups. The HIV response must take bolder action to remove
social and structural barriers to good health; this includes dismantling the global
war on drugs, repealing laws that criminalise same-sex relations, and eliminating
laws that criminalise HIV exposure, non-disclosure, or transmission.
3
The HIV response must make common cause with the global health field to achieve sustainable
health for all
Prioritised and sustained efforts are necessary to make health systems fit for the
purpose of delivering sustainable and people-centred care. National governments, international
donors, health professionals, and health advocates should work to create health systems
that are capable of ensuring universal health access and managing multiple health
problems simultaneously, with services tailored to the needs of individual patients.
Major new investments by countries and by international donors will be essential and
should focus on key elements of health systems, including strengthened primary care,
medical education and training, laboratory systems, systems for procurement and supply
management, and quality assurance and continual performance improvement. Health systems
should be transformed to create user-friendly and outcome-oriented service delivery
platforms for children, adolescents, and men as well as for marginalised populations
such as sexual minorities and people who inject drugs.
As an early step toward the long-term goal of integrating HIV and NCD services, existing
HIV service platforms should be adapted to enable the delivery of co-located and integrated
services for NCDs. HIV service providers must move beyond their singular focus on
viral suppression as the goal of HIV care and treatment and recognise (through adapted
training programmes, reconfigured clinics, and expanded monitoring and evaluation
indicators) prevention and management of NCDs as core HIV outcomes.
High-level global dialogue that includes the private sector is urgently needed to
mainstream a new paradigm for the development and provision of public goods. Drawing
on experience from the HIV response, originator pharmaceutical companies should, as
a standard practice, routinely enter into voluntary licenses for the full array of
their product portfolios. Voluntary licenses for medicines and other public goods
should maximise the coverage in LMICs using mechanisms such as sliding (ie, reasonable
royalty payments to address differences among countries in ability to pay). The viability
of a robust and flexible generics pharmaceutical industry must be preserved through,
for example, the protection of flexibilities under international intellectual property
agreements to ensure access to essential medicines and other public goods.
A review of global health governance architecture is needed. With the authorisation
of a resolution of the UN General Assembly, a high-level, time-limited, and independent
effort should be launched to develop a new global health governance architecture to
catalyse and guide a new era of global health solidarity. As a subset of this review
of global health governance, this independent exercise should generate concrete recommendations
for HIV governance, with the goals of eliminating duplication, enhancing coherence,
and refocusing global HIV governance on the overriding task of reviving global support
and commitment for the HIV response. Mechanisms for global health governance must
be democratic, inclusive, transparent, accountable, and grounded in a respect for
human rights and gender equity, with specific steps that ensure the input and engagement
of community, civil society, and other non-governmental actors.
The Commission recognises the urgent need to translate this vision of a new era of
global health solidarity into a concrete action plan. The Commission will work to
develop a clear, time-bound plan for implementing these recommendations in the coming
year.